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Introduction
Proper clinical studies (clinical trials) are essential to intro-
duce new therapeutic drugs, including antibacterial drugs. It
is extremely important for the welfare of people that clinical
studies are conducted in a reliable and smooth manner.
The Japanese Society of Chemotherapy established the
“Clinical Trial Committee”, “Consent Document Prepara-
tion Committee”, “Protocol Composition Committee
(Respiratory Tract, Urology)” and “Bridging Study Review
Committee” to establish standards necessary for upgrading
the level of clinical studies.
The Protocol Composition Committee (Respiratory
Tract) has prepared the drafts of the standard study proto-
col and Case Report Form (CRF) as herein published.
This protocol draft has been prepared in compliance
with “Guidelines for the Clinical Evaluation of Antimicro-
bial Drugs” prepared by the committee in 1998 basically
in every detail, and also in compliance with “General
Guidelines for Clinical Studies” (Notiﬁcation No. 380 of the
Evaluation and Licensing Division, PMSB, April 21, 1998)
and “Guidelines for the Clinical Evaluation of Antimicro-
bial Drugs” (Notiﬁcation No. 743 of the Evaluation and
Licensing Division, PMSB, August 25, 1998) in every
possible details.
The protocol and CRF drafts will be ﬁnalized as the
society’s standards in one year after the publication. Parties
concerned are invited to give forthright opinions in writing
to the secretariat of the society.
Without a great deal of cooperation of the staffs of the
pharmaceutical manufacturers currently engaged in the
development of new antimicrobial drugs, it would have
been impossible to prepare the protocol and CRF drafts,
and we would like to acknowledge their contribution.
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I Introduction: The Philosophy and Fundamental
Attitudes of the Committee
1. The underlying philosophy and the role of clinical
trial protocols
In preparing this protocol, every effort has been made to
use plain expressions so that principal investigators and all
other people who will be involved in a clinical trial can read
the protocol, understand its contents, and conduct the trial.
In addition, this protocol has been prepared so that the
ethical and scientiﬁc validity of clinical trials can be clearly
presented to third parties. In order to develop pharmaceu-
tical products efﬁciently, the sponsor of a clinical trial must
prepare a protocol that is easy to understand by fully utiliz-
ing this protocol as a reference.
(1) Assuring the safety and protection of the human rights
of subjects
The safety of subjects must be fully assured with respect
to the investigational product. It is also important to
protect the privacy of subjects in regard to information
obtained in the course of the clinical trial. This matter
is an aspect of the protection of human rights. We have
therefore decided to specify in this protocol rules for
the assurance of safety because such rules are impor-
tant from the viewpoints of safety and human rights.
(2) Assuring the reliability of the evaluation of the investi-
gational product
A clinical trial protocol must include the contents that
are stipulated in the following documents. GCP based
on the Guideline for Good Clinical Practice by the
ICH Steering Committee (Guideline for Good Clinical
Figure 1
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Practice: Ordinance No. 28, the Ministry of Health
and Welfare; Enactment of Guideline for Good Clinical
Practice: Notice No. 430, Pharmaceutical Affairs
Bureau, Ministry of Health and Welfare; and Imple-
mentation of Guidelines for Good Clinical Practice:
No. 445 Evaluation and Licensing Division, Pharma-
ceutical and Medical Safety Bureau, Ministry of Health
and Welfare), Verdict GCP (Notice No. 40, Central
Pharmaceutical Affairs Council, Ministry of Health
and Welfare), General Guidelines for Clinical Trials
(Notice No. 380, Evaluation and Licensing Division,
Pharmaceutical and Medical Safety Bureau, Ministry of
Health and Welfare) and Statistical Principles for Clini-
cal Trials (Notice No. 1047, Evaluation and Licensing
Division, Pharmaceutical and Medical Safety Bureau,
Ministry of Health and Welfare). Every effort has been
made to document evaluation methods clearly and in
detail, in order to eliminate differences in interpreta-
tion by each investigator, to make it possible to conduct
uniform trials and evaluate investigational products
correctly, and to verify the scientiﬁc and ethical validity
of the evaluation methods.
(3) Evaluation by authorities
The ethical and scientiﬁc validity of data collection and
data evaluation methods must be presented to the insti-
tutional review boards and regulatory authorities. We
have therefore clearly documented the validity of the
settings in this protocol.
(4) Increase the efﬁciency of the development of investiga-
tional products
It is generally considered that a protocol that is pre-
pared on a scientiﬁc basis decreases differences in inter-
pretation among clinical trial sites and evaluators. It
adds consistency to evaluation outcomes, and as such,
increases the reliability of the clinical trial. Establishing
the appropriate subject population and duration of the
trial will increase the efﬁciency of the development of
investigational products and minimize the level of ex-
posure of subjects to new substances and the effects of
the research-aspect of the trial; thus protecting the well-
being of subjects. Therefore, in preparing this protocol
we have paid great attention to establishing the
scientiﬁc basis of the protocol by marshaling various
scientiﬁc sources.
2. Fundamental attitude toward the preparation
of the clinical trial protocol
Attempts have been made to standardize clinical trial pro-
cedures. Research on Standardization of the Use of Anti-
microbial Agents was released in 1982 and amended in
1987. Guidelines for Clinical Evaluations of Antimicrobial
Agents was released by Japanese Society of Chemotherapy
in 1998. GCP was amended in 1997 (New GCP) and Good
Clinical Trial Protocol was produced by Japan Pharmaceu-
tical Manufactures Association in 1999.
Drugs that are newly developed are different from each
other in regard to type, antimicrobial activity, degree of
absorption and elimination, metabolism, administration
route, and indications to be treated. It is impossible to pre-
pare one protocol that can be applied equally to all develop-
mental drugs.
We have therefore described the important issues
for each type of antimicrobial agent and each phase of a
trial. Then, on the basis of these points, we have prepared
and presented a protocol that illustrates the funda-
mental structure that is common to all trials for antimicro-
bial agents. Figure 1 illustrates the structure of clinical
trials.
3. Establishing clinical evaluation methods, variables to
be assessed (endpoints) and duration of the observation
of progress
Based on Clinical Evaluation Methods for New Antimi-
crobial Agents for the Treatment of Respiratory Tract
Infections (1997, Japanese Society of Chemotherapy), the
disease categories for clinical evaluation of respiratory tract
infections are acute upper respiratory tract infections, sec-
ondary infection of chronic respiratory illness, and pneumo-
nia. In accordance with the same document, there are two
categories for the assessment of the efﬁcacy of the investiga-
tional product; they are clinical efﬁcacy assessment and
microbiological efﬁcacy assessment. Objective criteria will
be established for clinical efﬁcacy assessment, and will be
evaluated as “effective” or “ineffective”. Microbiological
efﬁcacy assessment will be conducted in accordance with
General Guidelines for Clinical Evaluation of Antimicro-
bial Agents, 1996. The safety of the investigational product
will be evaluated in terms of subjective and objective ad-
verse drug reactions, as well as abnormal laboratory test
values. Safety will be assessed in accordance with General
Guidelines for the Clinical Evaluation of Antimicrobial
Agents, 1996, and Assessment Criteria for Adverse
Drug Reactions and Abnormal Changes in Laboratory
Parameters in Clinical Trials for Antimicrobial Agents
(Chemotherapy 39:687, 1991; and Jpn. Chemother.43 (11),
1995, Amendment).
Efﬁcacy (clinical and microbiological) and safety
evaluations will be assessed comprehensively in order to
determine an overall assessment. The importance of each
variable will depend on the characteristics of the investiga-
tional product. The criteria for assessment must therefore
be speciﬁed in the protocol.
By convention, each variable for overall assessment is
assessed at the end of treatment (EOT). However, the cur-
rent international trend is to conduct assessment at the end
of the study (EOS).
Therefore, the timing of the evaluation of each variable
of acute upper respiratory tract infections and pneumonia is
set at: three days following the commencement of adminis-
tration, the day following the completion of administration,
and 7–10 days following the completion of administration.
The timing of evaluation of each variable of secondary
infection of chronic respiratory illness is set at: three
days following the commencement of administration, the
day following the completion of administration, and 7–
21 days following the completion of administration.
277
Efﬁcacy/safety variables (endpoints) and the timing of
evaluations vary in accordance with the characteristics of
the investigational product. Therefore, it is necessary to
designate variables as either primary efﬁcacy/safety vari-
ables (primary endpoints) or secondary efﬁcacy/safety vari-
ables (secondary endpoints). It is also necessary to clearly
document this division in the protocol. For example, pri-
mary endpoint: Clinical efﬁcacy at 7–10 days following the
completion of administration; secondary endpoints: Clinical
efﬁcacy on the day following the completion of administra-
tion, and microbiological efﬁcacy at 7–10 days following the
completion of administration. It is possible to choose mul-
tiple endpoints.
The observation of progress period must be long enough
to allow for follow-up, which may be deemed necessary for
safety reasons. The decision to conduct follow-up will be
based on the results of the overall assessment. The observa-
tion of progress period must be set in advance and from the
viewpoints of drug safety and ethics. The end of the obser-
vation period is the end of the study.
4. Fundamental attitudes in regard to assuring the quality
of clinical trials
The quality of all clinical trials must be high and it must be
assured. In order to comply with these requirements, the
sponsor must carefully select clinical trial sites and investi-
gators on the basis of thorough surveys and examinations of
the items described below. In addition, the sponsor must
describe the following items in detail in the protocol in
order to assure the quality of the trial. The sponsor must
instruct all investigators to comply with the protocol.
4-1 Clinical trial sites
In order to enhance and assure the quality of the trial, all
trial procedures conducted at trial sites must comply with
the New GCP. In fact, each trial site must have its own
regulations in regard to conducting clinical trials (standard
operating procedures), as well as institutional review board
(IRB) operating procedures. The IRB must comply with
the New GCP in regard to the number and requirements of
board members. In addition, the medical institution must
have a well-established system of precautions and emer-
gency procedures (e.g. an established method of communi-
cation in case of an onset of serious adverse events).
Therefore, it is desirable for trial sites to have their own
clinical trial administrative ofﬁce with designated in-
vestigator(s) and an adequate number of clinical research
coordinators (CRC), commensurate with the trial.
4-2 Investigators
Principal investigators and subinvestigators play an impor-
tant role in clinical trials. In particular, principal investiga-
tors are responsible for the quality of the clinical trial, which
is of utmost importance. Therefore, prior to selection of
principal investigators, it is necessary to conduct the inves-
tigations described below.
The principal investigators are required to have a high
level of medical knowledge in the area of the target of the
clinical trial. The sponsor should select principal investiga-
tors on the basis of the following credentials: Accredited
infection control doctor (ICD), a doctor who is accredited
by The Japanese Society of Clinical Pharmacology and
Therapeutics, a doctor who is registered by Japanese Soci-
ety of Chemotherapy as an instructor of clinical trials for
antimicrobial agents, membership of various of infectious
disease-related societies, the number of years experience in
the target ﬁeld, the number of years experience as an inves-
tigator, and the amount of time that candidates have avail-
able for carrying out the trial.
4-3 Clinical trial protocol
The protocol must describe in the sections listed
below, clearly and in detail, the means by which the quality
of the trial will be improved, maintained and assured.
The aspects of quality that must be addressed are in respect
to the subjects, the trial sites, the investigators, and the
sponsor. The trial must then comply with these descriptions.
The sections are “Compliance with GCP”, “Indications
studied and inclusion/exclusion criteria”, “Consent obtain-
ment from and information supply to subject”, “Compli-
ance with the protocol”, “Documentation of the case report
form”, “Acceptance of direct access to source data/
documents”, “Acceptance of monitoring for quality control
and quality assurance of the clinical trial” and “Record
storage”.
5. The necessity of late phase II clinical trials
Late phase II clinical trials were conventionally conducted
to verify the appropriateness of dosages that were estimated
on the basis of the results of pre-clinical studies and phase
I clinical trials. They were also conducted to explore the
recommended clinical dosages for double-blind studies in
phase III clinical trials. However, the opposite results for
clinical efﬁcacy were often observed between high-dose and
low-dose groups because an insufﬁcient number of cases
were studied.
From these circumstances, there is a growing belief
that it is suitable to explore the appropriate dosage in
non-clinical studies, phase I clinical trials, un-blind studies
in phase II clinical trials, and un-blind studies in phase
III clinical trials. Furthermore, as late phase II clinical trials
are usually not conducted in Western countries, it is not
necessary to conduct late phase II clinical trials if the appro-
priate dosage can be determined from other phases of the
trial.
6. Control drugs in controlled studies
Comparison with other drugs: Control drugs were selected
from drugs in the same category as the investigational
product and for which the results of clinical evaluation
have already been established. However, control drugs
will henceforth not need to be in the same category as the
investigational product, and they may be any currently
available drugs. It is possible to conduct controlled studies
with control drugs of a different category as long as the basis
for the selection of the control drugs is speciﬁed. In such
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cases, it is important to consider what types of characteris-
tics constitute the most suitable control drug in order to
clarify the superior characteristics of the investigational
product.
Controlled studies with concomitant drugs: Previously,
controlled studies conventionally referred to a comparative
study involving the investigational product and another
drug. However, if the antimicrobial agent that is being de-
veloped is expected to be frequently used in conjunction
with a certain drug, or if synergy between the investiga-
tional product and a concomitant drug is anticipated, it is
desirable to conduct controlled studies with the concomi-
tant drug.
7. The severity of the diseases of subjects and
evaluation methods
Previously, a subject could participate in trials only if his/
her disease was either mild or moderate. However, it is
possible to include subjects with severe diseases in accor-
dance with the characteristics of antimicrobial agents. In
such cases, it is necessary to clarify (in the severity criteria)
the distinction between infectious diseases and underlying
diseases. In addition, it is necessary to establish new clinical
evaluation methods for each disease. For example, you may
select the prognosis of subjects following the commence-
ment of the clinical trial, or the improvement in the quality
of life (QOL) as the primary efﬁcacy variable (primary
endpoint), or secondary efﬁcacy variable (secondary end-
point). Variables are not necessarily limited to clinical efﬁ-
cacy and microbiological efﬁcacy.
These points must be fully documented in the protocol.
8. Clinical trials in accordance with clinical pathologic
classiﬁcations of respiratory tract infections
Pneumonia can be classiﬁed into many different clinical
pathological categories (e.g. Community acquired pneumo-
nia, nosocomial pneumonia, ventilator associated pneumo-
nia (VAP), pneumonia without an underlying disease, and
nursing home acquired pneumonia). This also applies to
secondary infection of chronic respiratory illness. It is pos-
sible to design a clinical trial in which the characteristics of
the antimicrobial agent being developed are veriﬁed on the
basis of the efﬁcacy of each pathological classiﬁcation of
infectious disease. In this case, the protocol will be very
different from that presented in this paper. Ensure that the
protocol is prepared by fully considering the fundamental
attitudes described in this paper.
9. Cases in which a small dose of macrolide has been
administered over a long period
There are many cases in which a small dose of macrolide
(e.g. erythromycin) has been administered over a long
period in order to control a chronic respiratory illness such
as diffuse panbronchiolitis (DPB). We think that the use-
fulness of this treatment has been proven.
In the past, some treatments have been discontinued
in order to conduct clinical trials, although in actual
clinical situations treatments are not discontinued simply to
administer antimicrobial agents that have been recently re-
leased on the market. We do not think it is necessary to
discontinue long-term administrations for clinical trials,
except in cases where the administered drug is thought
to signiﬁcantly inﬂuence the evaluation of the investiga-
tional product if used in conjunction with the investigational
product.
10. Establishment of diagnostic criteria
Although it is very rare to identify the pathogenic bacteria
for respiratory tract infections, considerable effort should
be given to a diagnosis on the basis of microbiological ﬁnd-
ings. If bacteria are isolated, it is comparatively easy to
diagnose the disease. However, it is difﬁcult to isolate
viruses, mycoplasmas, chlamydias and legionellas in order
to culture them. Therefore, serum antibody titer measure-
ments, antigen detection or gene examinations are often
carried out in order to diagnose diseases. In these cases, it
is necessary to fully consider the circumstances and pos-
sible outcomes, prior to the commencement of the trial,
and determine the test method(s) and diagnostic criteria
in advance.
11. Necessity of intracutaneous test in the development
of injections
Intracutaneous tests that are conducted in clinical trials
for antimicrobial agents (primary -lactam antimicrobial
agents) are not regarded as useful for predicting the risks of
anaphylactic shock and other allergic reactions. Indeed,
the tests are not conducted in any western countries.
Although our committee sees intracutaneous tests as
not necessary, we have a history of conducting them in
Japan. It is necessary to be aware that we will collect
evidence to support the abolishment of the tests in the
future.
When conducting the clinical trial, it is necessary to be
fully aware of the risk of the onset of allergic reactions,
including shock, due to the investigational product. It is
necessary to prepare readily available measures and re-
sponse for such cases.
12. Other considerations
The following topics will be discussed in each designated
section: The basic principles of each phase of a clinical trial
(early phase I, late phase II, phase III and phase IV);
criteria for each disease (acute upper respiratory tract
infections, secondary infection of chronic respiratory
illness and pneumonia); and important points for each type
of antimicrobial agent (-lactam antimicrobial agents,
macrolides, quinolones, new antimicrobial agents, oral
drugs and injections).
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laryngitis are included in this category. However, acute
rhinitis, acute sinusitis and acute tympanitis are usually
treated in otorhinology departments and are therefore not
included here. -streptococcus is the most common patho-
genic bacteria of acute tonsillitis and peritonsillar abscess,
followed by pneumococcus, Staphylococcus aureus and
Haemophilus inﬂuenzae. In most cases, the pathogenic
microorganisms of acute pharyngitis and acute laryngitis
are viruses. If these viruses damage the mucous membranes
of the respiratory tract, secondary infections occur in that
area. The most common pathogenic bacteria of secondary
infections are Streptococcus pyogenes, followed by pneumo-
coccus, Staphylococcus aureus and Haemophilus inﬂuenzae.
Acute upper respiratory tract infections that may be
studied for the purposes of developing oral antimicrobial
agents to be used in the ﬁeld of internal medicine are acute
tonsillitis and acute bacterial pharyngitis/laryngitis. Acute
upper respiratory tract infections, which may be studied for
the purposes of developing antimicrobial injections to
be used in the ﬁeld of internal medicine, are peritonsillar
abscess and retropharyngeal abscess.
2. Outline of acute lower respiratory tract infection
(acute bronchitis)
Acute lower respiratory tract infection is acute bronchitis.
In general, bronchitis occurs because the upper respiratory
II Outline of Respiratory Tract Infectious Diseases
and Indications Studied in Clinical Trials
Respiratory tract infections can be divided into three
groups in accordance with the infected area: Respiratory
tract (upper and lower), lung (parenchyma and intersti-
tium), and pleura. From the viewpoint of clinical trials for
antimicrobial agents, diseases that develop in these parts
include upper respiratory tract infections (acute), lower res-
piratory tract infections (acute and chronic), pneumonia,
pulmonary suppuration, and acute purulent pleurisy. Of
these, pneumonia and chronic lower respiratory tract infec-
tion (secondary infection of chronic respiratory illness) are
the most important diseases.
The following are brief descriptions of each disease.
I. Acute respiratory tract infection
1. Outline of acute upper respiratory tract infection
Acute upper respiratory tract infection is a general term for
any acute infections that develop in the upper respiratory
organs, including the nose, mouth and glottis. Another
name is common cold syndrome. Acute rhinitis, acute
sinusitis, acute tympanitis, acute tonsillitis, peritonsillar ab-
scess, acute pharyngitis, retropharyngeal abscess and acute
Names of indications categorized as respiratory tract infections (comparison between the USA and Japan)
Indications deﬁned by FDA1) Translation Corresponding Japanese namesof indications2)
Community acquired pneumonia Community acquired pneumonia Pneumonia
Nosocomial pneumonia Nosocomial pneumonia Pneumonia(Nosocomially acquired pneumonia) (Nosocomially acquired pneumonia)
Acute exacerbation of chronic Acute exacerbation of chronic Secondary infection of chronic
bronchitis bronchitis respiratory illness
Acute exacerbation of chronic Acute exacerbation of chronic Secondary infection of chronic
obstructive pulmonary disease obstructive pulmonary disease respiratory illness
Secondary bacterial infection of Secondary bacterial infection of Acute bronchitis
acute bronchitis acute bronchitis
Streptococcal pharyngitis/tonsillitis Streptococcal pharyngitis/tonsillitis Pharyngitis/tonsillitis
1) The name of each indication is followed by their pathogenic bacteria names (e.g. tonsillitis due to Staphylococcus aureus, pneumonia due to
Streptococcus pneumoniae), with the exception of Streptococcal pharyngitis/tonsillitis.
2) In Japan, there is no uniform system of classiﬁcation, and usage has been changing over time. As this may create confusion in clinical situations,
our society has suggested to the Ministry of Health, Labor and Welfare to unite classiﬁcations as follows (as of 2000).
a. Acute bronchitis includes bronchitis and acute bronchitis.
b. Currently, all infectious bacterial diseases that develop in addition to a chronic respiratory illness are described as “secondary infection of
chronic respiratory illness”. Examples include acute exacerbation of chronic bronchitis, bronchiectasis  infection, bronchial asthma 
infection, pulmonary emphysema  infection, pneumoconiosis  infection, inveterate tuberculosis  infection, and interstitial pneumonia
 infection.
c. All bacterial pneumonia, with the exception of atypical pneumonia, are described as pneumonia. This is the same as conventional
categorization. If the indication is pneumonia due to mycoplasma, chlamydia, legionella, Methicillin-resistant Staphylococcus aureus
(MRSA), the name is described as “pneumonia (including XXXX pneumonia)”.
d. Conventional pulmonary abscess and pulmonary gangrene are described as pulmonary suppuration.
e. Conventional thoracic empyema and pleurisy are described as thoracic empyema.
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tract infection spreads to other areas along the airway.
Therefore, the pathogenic microorganisms of this disease
are mainly the same as those in upper respiratory tract
infections. However, the lower respiratory tract is more
susceptible to primary and secondary bacterial infections
than is the upper respiratory tract. The most common patho-
genic bacteria of acute bronchitis are Haemophilus inﬂu-
enzae, followed by pneumococcus and Moraxella catarrhalis.
In epidemic seasons, mycoplasmas are often the patho-
genic microorganisms of acute upper/lower respiratory
tract infections, as is Chlamydia pneumoniae. However, the
symptoms and ﬁndings of the inﬂammation caused by these
pathogenic microorganisms may remain mild. In addition,
the antimicrobial agents that are effective against these
microorganisms are different from the agents that are effec-
tive against the bacteria mentioned above. We therefore
established different criteria for cases in which bronchitis
is due to these microorganisms.
3. Pathological classiﬁcations of acute upper/lower
respiratory tract infections studied in clinical trials
Indications to be studied for antimicrobial agents are gener-
ally bacterial infections. Therefore, secondary bacterial in-
fections that occur in the upper/lower respiratory tract after
temporary viral infections are valid indications.
The indications studied in clinical trials of acute respira-
tory infections are infections due to bacteria, not viruses.
For example, fever, pharyngeal pain, cough and sputum are
observed in both viral and bacterial infections, but icteric
sputum, leukocytosis, skeocytosis and neutrophilia are ob-
served only in bacterial infections. Cases in which these
symptoms/ﬁndings are observed are eligible to be subjects
in clinical trials.
Acute respiratory tract infections are usually mild to
moderate. It is very rare that these infections are catego-
rized as severe. Therefore, patients with such infections are
usually outpatients, and only oral antimicrobial agents are
used in drug therapy.
We exclude acute respiratory tract infections that has
developed in patients with chronic respiratory illness from
this category, as it should be regarded as a secondary infec-
tion of a chronic respiratory illness.
4. Trial-subject criteria for cases with acute bacterial
upper/lower respiratory tract infections
Cases are eligible to be subjects in clinical trials if the symp-
toms and ﬁndings of upper/lower respiratory tract infec-
tions are observed, and they satisfy (1) and at least two of
the other four criteria ((2), (3), (4) or (5)).
(1) Bacteria that are suspected as pathogenic microorgan-
isms have been detected in a specimen such as sputum,
or are likely to be detected, or a good specimen has
been obtained (e.g. a specimen that includes plug
of pus, purulent secretion or purulent sputum), even
though pathogenic microorganisms have not been
detected.
(2) Leukocytes 8000/mm3
(3) Rod neutrophils 10%
(4) CRP 0.7mg/dl (or CRP exceeds the upper limit of the
relevant institute)
(5) Body temperature 37.0°C
5. Trial-subject criteria for cases with infections due to
mycoplasma or chlamydia
Cases are eligible to be subjects in clinical trials if the symp-
toms and ﬁndings of upper/lower respiratory tract infec-
tions are observed and they satisfy any of the categories in
(1), and at least three of the other six criteria ((2), (3), (4),
(5), (6) or (7)).
(1) (i) Infections due to mycoplasma (hereinafter, M): A
fourfold (or greater) increase in antibody titer in
paired sera, a single CF antibody titer of 1 :64 or
greater, or a single HA antibody titer of 1 :320 or
greater.
(ii) Infections due to chlamydia (hereinafter C): A
fourfold (or greater) increase in antibody titer in
paired sera, or a single CF antibody titer of 1 : 32
or greater.
(iii) Antigen detection tests or gene detection tests
(such as ﬂuorescent antibody technique, immuno-
enzyme technique, DNA probe test and PCR test)
for M or C were positive.
(2) Leukocytes 8000/mm3
(3) Rod neutrophils 10%
(4) CRP 0.7 mg/dl (or CRP exceeds upper limit of the
relevant institute)




1. Outline of diseases
Pneumonia is an acute lung parenchyma infection due to
various microorganisms. It is the primary disease of respira-
tory tract infections. Pathogenic microorganisms include
general bacteria, atypical microorganisms (mycoplasmas,
chlamydias and legionellas), viruses, acid-fast bacteria,
fungi and protozoa. The indications to be studied in clinical
trials to develop antimicrobial agents are pneumonia due to
general bacteria and pneumonia due to atypical micro-
organisms. Pneumonia due to other microorganisms
should be evaluated and assessed on the basis of criteria
established in accordance with the characteristics of each
microorganism.
If the pathogenic microorganisms are suspected to be
bacteria, sputum discharged from the mouth is usually
tested to obtain conﬁrmation. It is somsetimes difﬁcult to
obtain sputum in cases of pneumonia, and it may therefore
be necessary to take measures such as forced expectoration
by means of gargling or a strong cough, guided expectora-
tion by means of nebulizer, tapping or postural drainage. If
281
these measures do not work, use a throat swab or nasophar-
ynx scraping as a substitute. If a high fever is observed
shortly after the patient develops the infection, it is desir-
able to conduct blood culturing without limiting the bacte-
ria type because the patient is possibly suffering bacteremia.
Ideally, the pathogenic microorganisms can be identiﬁed
so that only appropriate cases are included in clinical trials
and the clinical efﬁcacy of the investigational antimicrobial
agent can be evaluated correctly. However, in actual clinical
situations, we cannot avoid commencing antimicrobial drug
therapy without knowing the pathogenic microorganism.
As such, the probable pathogenic bacteria must be inferred
from the subject’s background. The basis of inclusion in the
clinical trial will be consideration of the antimicrobial activ-
ity of the investigational product, the pharmacokinetics of
the investigational product (distribution to lungs), and ad-
verse drug reactions due to the investigational product. If
it is decided that the case will be included, an appropriate
dosage will be determined by calculating the concentration
of the drug in the lesion (lesion size is determined by the
results of chest X-rays).
Pneumonia is roughly divided into two groups: commu-
nity acquired pneumonia and nosocomial pneumonia.
Community acquired pneumonia occurs in people who live
in a community outside the hospital. Pneumonia with a mild
underlying disease/complication(s) is included in commu-
nity acquired pneumonia. However, if patients are elderly
and have low ADL, they must be excluded from some
phases of the clinical trial, even if their disease is community
acquired pneumonia. If a certain level of organic changes
are observed in the tract and alveoli, the changes cause
infections repeatedly, and there is clear evidence of a respi-
ratory tract infection over a wide area, the patient must be
diagnosed with a respiratory tract infection, even if their
chest X-rays display a certain spread of shading (alveolitis).
A key issue in the diagnosis of community acquired pneu-
monia is that the patient lived in a community outside the
hospital when they developed pneumonia. They may or
may not have a mild underlying disease/complication(s). By
contrast, nosocomial pneumonia occurs in people who are
hospitalized. In general, pneumonia that develops within 48
hours of hospitalization is called nosocomial pneumonia.
This type of pneumonia develops from a disease that a
patient had at the time of hospitalization. The pathogenic
microorganisms of nosocomial pneumonia may be micro-
biologically very speciﬁc because they develop in a speciﬁc
environment, i.e. within hospitals.
As we described in the section on acute respiratory tract
infections, mycoplasmas are often detected as pathogenic
microorganism of pneumonia during epidemic seasons.
In addition, the number of cases in which Chlamydia
pneumoniae is the pathogenic microorganism of pneumonia
increases in such a season. If they are pathogenic microor-
ganisms, the symptoms and ﬁndings of inﬂammation remain
mild in many cases. In addition, the antimicrobial agents
that are effective against these microorganisms are different
from those that are effective against other bacteria. We
have therefore established different criteria for cases of
pneumonia due to these microorganisms.
Plain chest X-rays are usually used to examine shading in
the lungs.
i) In order to observe shading accurately, it is desirable
to use conventional methods. The use of computed radiog-
raphy (CR) should be avoided if possible, as exudation (the
most fundamental sign of inﬂammation) is not fully pro-
jected in these images if the intensity of exudation does not
exceed a minimum level.
In some cases it is best to conduct computed tomography
(CT) because CT indicates exudation more clearly than
conventional plain X-rays or CR images. If shading is ob-
served in CT images, use the CT images primarily to evalu-
ate shading and calculate the score. In order to reach a
ﬁnal score, add up all shaded areas, and then consider the
shading of plain conventional X-rays or CR images. (As a
scoring method for CT images has yet to be established,
conventional scoring methods must be used with some
adaptation until this is achieved.)
ii) Chest images are usually taken from the anterior per-
spective and it is therefore easy to recognize the spread of
shading in the left/right and up/down dimensions. However,
it is difﬁcult to see the depth of spreading (e.g. whether
shading has spread to the sub-segment such as S3b or not).
It is necessary to take lateral images if the depth of spread
needs to be examined.
iii) The intensity of shading depends on the intensity of
exudation (the most fundamental sign of inﬂammation). If
shading is extremely dark, an extra point is added to the
score in the rating the expansion of pneumonia. Reduction
in the density of shading following administration of anti-
microbial agents must be evaluated accordingly.
2. Disease level of subjects who are eligible to participate
in clinical trials
The severity of an infectious disease is an extremely impor-
tant criterion in determining whether a patient can be
included in clinical trials for antimicrobial agents. The
severity of the underlying disease/complication(s) is also
important. The seriousness of a patient’s condition is deter-
mined by comprehensively assessing the severity of the two
aforementioned conditions.
If the investigational antimicrobial agent is an oral drug,
patients who are eligible to be subjects are primarily outpa-
tients in which the severity of the infectious disease is mod-
erate or less than moderate, and with a mild underlying
disease/complication(s) (if any).
By contrast, if the investigational antimicrobial agent is
an injection, only inpatients may become subjects. In the
past, the severity of an infectious disease in a patient who
was eligible to participate in clinical trials was moderate or
less; however, it is now possible to include patients with
severe infectious diseases in trials (depending on the char-
acteristics of the investigational product).
A patient with a severe underlying disease/compli-
cation(s) is categorized as serious in the classiﬁcation of the
seriousness of a patient’s condition, even if the severity of
the infectious disease is mild. Considerable caution is re-
quired in clinically evaluating the investigational antimicro-
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bial agent from test results obtained from these patients. In
addition, a different protocol needs to be prepared for
evaluation.
3. Trial-subject criteria for cases with pneumonia
Cases are eligible to be subjects in clinical trials if the symp-
toms and ﬁndings of pneumonia are observed, and if they
satisfy the following criteria.
(1) Chest X-rays or CT images project a newly developed
shadow.
(2) Acute inﬂammatory ﬁndings such as neutrophilia,
skeocytosis (rod neutrophils 10%), an increase in
CRP (1.0mg/dl or more) and an increase in ESR are
observed in hematological tests.
Both the above criteria and at least two of the following
four criteria must be satisﬁed.
(3) Fever (37°C)
(4) Respiratory system-related symptoms such as cough,
sputum (purulent sputum), chest pain and breathing
difﬁculty
(5) Moist rale
(6) Microorganisms that are suspected to be pathogenic
microorganisms were detected from specimens such as
sputum, or a good specimen that is likely to contain
pathogenic microorganisms can be obtained.
4. Trial-subject criteria for cases with Mycoplasma(M)
pneumonia or Chlamydia(C) pneumonia
Cases are eligible to be subjects in clinical trials if symptoms
and ﬁndings for M pneumonia and C pneumonia are ob-
served, and if they satisfy either (1) or (2), and at least three
of the other six criteria ((3), (4), (5), (6), (7) or (8)).
(1) Chest X-rays or CT images project a newly developed
shadow (shading is seen in the interstitium).
(2) (i) Infections due to mycoplasma (hereinafter, M): A
fourfold (or greater) increase in antibody titer in
paired sera, in a single CF antibody titer of 1 :64 or
greater, or a single HA antibody titer of 1 :320 or
greater.
(ii) Infections due to chlamydia (hereinafter C): A
fourfold (or greater) increase in antibody titer in
paired sera, or a single CF antibody titer of 1 :32 or
greater.
(iii) Antigen detection tests or gene detection tests
(such as ﬂuorescent antibody technique, immuno-
enzyme technique, DNA probe test and PCR test)
for M or C were positive.
(3) Leukocytes78000/mm3
(4) Rod neutrophils 10%
(5) CRP 0.7 mg/dl (or CRP exceeds upper limit of the
relevant institute)




Pulmonary suppuration is a new name for pulmonary ab-
scess and pulmonary gangrene. This disease is deﬁned as
suppurative necrosis of the lung parenchyma. The most
important point in antimicrobial drug therapy for this dis-
ease is that primary pathogenic bacteria are anaerobes.
Aerobes (Gram negative bacillus such as colibacillus and
Gram positive coccus such as Streptococcus) follow and
exacerbate infections originally due to anaerobes. Pulmo-
nary suppuration is the second most common bacterial in-
fection of the lung parenchyma (bacterial pneumonia is the
most common). In regard to clinical trials, this disease can
be regarded as the same as pneumonia. Therefore, trial-
subject criteria for cases with pneumonia and evaluation
methods for pneumonia can be used for this disease.
However, anaerobes must be regarded as the important
bacteria in microbiological testing in the case of pulmonary
suppuration.
IV. Secondary infection of chronic respiratory illness
1. Disease outline
Patients with chronic bronchitis, bronchiectasis, diffuse
panbronchiolitis (DPB), pulmonary emphysema or inveter-
ate sclerosing tuberculosis often have recurring infections in
the lower respiratory tract. Infections are based on organic
changes in the lower respiratory tract.
Each infection is an acute infection that occurs in
immune-compromised people. This disease is sometimes
called a chronic respiratory tract infection because infection
occurs repeatedly and without interval. We call this disease
secondary infection of chronic respiratory illness. The
most important bacteria of this infectious disease are
Haemophilus inﬂuenzae, followed by pneumococcus and
Moraxella catarrhalis. These bacteria are substituted by
Pseudomonas aeruginosa after long term repeated infec-
tions, which results in refractory superinfection.
2. Disease level of subjects who are eligible to participate
in clinical trials
In the case of secondary infection of chronic respiratory
illness, the seriousness of the condition is assessed on the
basis of the severity of the infectious disease and underlying
disease/complication(s). Secondary infection of chronic
respiratory illness is based on organic changes in the lower
respiratory tract. Infection occurs repeatedly and without
interval. Organic changes spread as the infection reoccurs.
The original pathogenic bacteria are replaced by Pseudo-
monas aeruginosa. Pseudomonas aeruginosa causes super-
infection and then becomes established. In this case, even if
the severity of the infectious disease is mild, it is difﬁcult to
obtain antimicrobial effects from antimicrobial agents be-
cause organic changes in the lower respiratory tract are
signiﬁcant over a broad area. Therefore, the patient’s condi-
tion is categorized as serious if (i) the severity of the under-
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lying disease/complication(s) is severe, even if the severity
of the infectious disease is mild to moderate, or (ii) the
severity of the infectious disease is severe and the severity
of the primary disease/complication(s) is moderate. Cur-
rently, such cases are very difﬁcult to treat and it is not
appropriate to include such patients in the subject group.
However, these patients must be treated with antimicrobial
agents in actual clinical situations. In the future, it is neces-
sary to develop an antimicrobial agent to treat these serious
cases, and to conduct clinical trials of the antimicrobial
agent as an independent or concomitant drug.
If organic changes in the respiratory tract of DPB
patients are mild, the most common pathogenic bacteria
at the time of onset of infection are Haemophilus inﬂuenzae
followed by pneumococcus. However, these bacteria are
more easily substituted with Pseudomonas aeruginosa in
DPB patients than in patients with other secondary infec-
tions of chronic respiratory illnesses. As DPB patients
develop opportunistic infections more frequently than pa-
tients with secondary infection of chronic respiratory illness
and are more difﬁcult to treat, it is at present inappropriate
to include them in a group of subjects for a clinical trial. If
organic changes in DPB patients are mild (DPB chest X-ray
classiﬁcation [by Tanimoto and Nakata]: type I [penetration
increased, no granulated shading], type II [total granulated
shading area not exceeding area of one lung], or type III
[granule-shape shadows entirely cover the lungs but no
“tramline shadows” or “ring shadows”]), these patients may
currently be included in the subject-group. In the future,
however, it will be necessary to include more severe cases
such as type IV (ﬁndings of type III and “tramline shadows”
in lower lung), and type V (ﬁndings of type IV and “ring
shadows”) for the same reason that we described above.
3. Trial-subject criteria for cases with M pneumonia
and C pneumonia
Cases are eligible to be subjects in clinical trials if sym-
ptoms and ﬁndings of secondary infection of chronic respi-
ratory illness are observed, and if they satisfy the following
criteria.
Prerequisites
(1) Onset of coughing and sputum, increase in sputum
volume or puruloid sputum
(2) Increase in CRP (0.7mg/dl, or CRP exceeds the
upper limit of the relevant institute)
It is desirable to satisfy the following criteria.
(3) Pathogenic bacteria are identiﬁed.
(4) Fever (37°C)
(5) Leukocytosis in peripheral vessels (8000/mm3, or in
excess of the upper limit of the relevant institute)
V. Acute thoracic empyema
In regard to pleurisy, acute thoracic empyema (acute puru-
lent pleurisy) caused by bacteria is included in the indica-
tions to be studied in clinical trials. The most common cause
of this disease is the spread of inﬂammation from pneumo-
nia or pulmonary suppuration to the pleura. The second
most common cause is the spread of inﬂammation from a
subphrenic abscess. Thoracic empyema sometimes occurs
in patients with sepsis because bacteria have spread to the
pleura via the blood. In some cases, it is not known where
the bacteria enter the body or by which route it traveled.
The best cases to be subjects in these clinical trials are
patients in which the inﬂammation caused by this disease is
limited to the pleura. If patients suffer from inﬂammation of
the organs adjacent to the pleura, they are not appropriate
to be subjects. Patients with only a small amount of ﬂuid in
the pleural cavity, and who can be treated with drug therapy
only (i.e. without drainage), are also suitable to be subjects.
As treatment for this disease is usually conducted within
a hospital, drugs are mainly in the form of an injection. The
severity of the infectious disease and underlying disease/
complication(s) in a patient who participates in a clinical
trial should be moderate or less than moderate. If more
than a certain volume of ﬂuid is observed in patients and the
severity of the infectious disease is more than moderate, it is
practical to carry out antimicrobial therapy in conjunction
with drainage. In this case, it is necessary to establish dif-
ferent evaluation criteria to evaluate the antimicrobial
therapy.
III Approach to Each Phase of a Clinical Trial
The standard approach to developing antimicrobial agents
is described in Guidelines for the Clinical Efﬁcacy of Anti-
microbial Agents (Notice No.743, August 25, 1998). This
publication is based on researches by our society, and issued
by the Evaluation and Licensing Division, the Pharmaceuti-
cal and Medical Safety Bureau, the Ministry of Health and
Welfare. It presents clearly the objectives of each phase
(phases I–IV) and the sequence of fundamental consider-
ations in the development of antimicrobial agents.
By contrast, General Guidelines for Clinical Trials (No-
tice No. 380, Evaluation and Licensing Division, Pharma-
ceutical and Medical Safety Bureau, Ministry of Health
and Welfare, April 21, 1998) recommends a diverse de-
velopment style that is structured in accordance with the
objectives of clinical trials, the circumstances, and the char-
acteristics of the investigational product, rather than con-
ventional uniform trials based on phase progression. In this
publication, trials that are conducted in order to obtain
approval are divided into three categories; they are clinical
pharmacological studies, exploratory studies and conﬁrma-
tory studies. In this publication, trials that are conducted
after the product has been released to the market are called
therapeutic use. The publication does not consider it appro-
priate to categorize clinical trials by phase because some
trials involve several phases. The following ﬁgure demon-
strates the relationship between the conventional trial de-
lineation that is based on phase (phases IIV), and the trial
delineation that is based on the new category recommenda-
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tions. For example, although studies categorized as clinical
pharmacological studies are generally conducted in phase I
of clinical trials, they should also be conducted in other
phases if required.
The following table shows the classiﬁcation of clinical
studies by objective and the interrelation with conventional
study phases for the cardinal issues to consider when devel-
oping new antibacterial drugs.
This table is based on General Guidelines for Clinical
Trials (Notice No. 380, Evaluation and Licensing Division,
Pharmaceutical and Medical Safety Bureau, Ministry of
Health and Welfare, April 21, 1998).
Table. Classiﬁcation of clinical studies sorted by objective
Study type Objective Phase Study examples
Clinical (1) Drug tolerance evaluation I • Tolerance studies
pharmacological • Inﬂuence on indigenous bacteria (inﬂuence on intestinal
studies bacterial ﬂora)
(2) Pharmacokinetic and I • Single/repeated-dose pharmacokinetic and
pharmacodynamic – pharmacodynamic studies
examinations IV • Pharmacokinetic studies in elderly people, children,
people with hepatic/renal dysfunction
• Drug interaction studies
Exploratory (1) Exploring safety and efﬁcacy II • Comparatively short-term exploratory studies in
studies patients selected on the basis of speciﬁc criteria.
(2) Verifying recommended II • Conﬁrmatory dosage studies (from viewpoint of safety)
clinical dosage
(3) Exploring clinical II • Studies to determine the clinical advantages of
characteristics the investigational product
Conﬁrmatory (1) Verifying non-inferiority or II • Controlled studies involving other drugs
studies superiority of efﬁcacy – * This may include conﬁrmatory studies of the
III recommended clinical dosage
(2) Conﬁrming indications III • Conﬁrmatory studies of efﬁcacy and safety in regard to
(expanding the range of indications that were not included in comparison tests.
indications)
Therapeutic use • Collecting further IV • Drug Use Investigation
information on appropriate • Special Investigation
usage • Post-marketing studies
* Examining the drug sensitivity of bacteria (drug-
resistant) Continuous examination of drug interactions







In addition, Ethnic Factors in the Acceptability of For-
eign Clinical Data (Notice No. 672, Evaluation and Licens-
ing Division, Pharmaceutical and Medical Safety Bureau,
Ministry of Health and Welfare) was issued on August 11,
1998. This publication made it possible to use clinical data
obtained in foreign countries as data for product approval
in Japan. The overseas clinical data must be applicable to
Japanese people and the trials must have been conducted in
compliance with new GCP (Ordinance No. 28 of the Minis-
try of Health and Welfare, Guideline for Good Clinical
Practice, 1997). As such, this publication has made trial
designs for developing antimicrobial agents more diverse
(e.g. bridging studies may now be conducted).
In this chapter, we describe clearly the objectives of each
study category in accordance with General Guidelines for
Clinical Trials.
1. Clinical pharmacological studies (mainly in phase I
clinical trials)
These studies are conducted in order to determine the clini-
cally safe dose-range of the investigational product, and to
conﬁrm the pharmacokinetics of the investigational prod-
uct, such as absorption and excretion. The subjects of this
study are usually normal adult male volunteers. In addition,
this study aims to obtain information about the pharmaco-
kinetics of the investigational product and its interactions
with other drugs in a wide range of patient groups that are
expected to receive it as a medication when it has been
released.
(1) Tolerance evaluation
The studies in this category aim to conﬁrm drug tolerance
within the range of doses that are necessary for use in other
studies conducted later in the clinical trial. They also aim to
understand the characteristics of anticipated adverse
events. Single-dose studies and repeated-dose studies are
usually conducted. Dosage in single-dose studies is based on
information obtained from non-clinical studies, previous
clinical trials conducted in foreign countries, and similar
types of drugs. In single-dose studies, the relationship be-
tween dosage and the onset of adverse drug reactions or
abnormal laboratory test values is examined. Dose per ad-
ministration in the repeated-dose studies are set to the
maximum clinical dose that has been determined on the
basis of the results of single-dose studies. The interval be-
tween administrations is the period that is necessary for the
concentration of the drug in the blood to reach a steady
state. If it is suspected that the investigational product will
inﬂuence indigenous bacterial ﬂora, or cause adverse drug
reactions, these issues must be examined.
If the investigational product has the potential to be
toxic to healthy people, it is necessary to examine the in
vivo pharmacokinetics and possible adverse drug reactions
using patients who suffer from the indications to be studied.
In this case, it is necessary to determine the dose that is
expected to be effective for the indications so that patients
can beneﬁt from the study.
(2) Pharmacokinetic and pharmacodynamic examinations
In pharmacokinetic studies, drug clearance is evaluated,
and the possibility of unchanged drug and metabolite accu-
mulation is investigated. In addition, the inﬂuence of meals
on the pharmacokinetics is examined. Pharmacokinetic
studies involving elderly people, children, and people with
hepatic/renal dysfunction may be conducted if required.
If necessary, drug interactions may be examined using
drugs that may be used as concomitant drugs in clinical
applications.
In addition, drug distribution to the lesion site will be
studied.
In some cases, studies will compare the pharmacokinet-
ics of Japanese and non-Japanese people in order to exam-
ine the validity of applying the results of clinical trials
conducted in foreign countries to Japanese people.
2. Exploratory studies (mainly in phase II clinical trials)
These are small-scale studies conducted in order to ex-
plore safety and efﬁcacy, to verify clinical dosage recom-
mendations, and to explore the clinical characteristics of
drugs.
If the recommended clinical dosage has already been
established in reliable clinical trials conducted in foreign
countries and there is sufﬁcient information in regard to
safety and efﬁcacy, or if it is judged that the results of
foreign clinical trials in regard to antimicrobial activities
and pharmocokinetics/pharmocodynamics are applicable to
Japanese people, it is possible to omit the exploratory study
in Japan. In this case, the recommended clinical dosage for
Japanese people must be conﬁrmed in the conﬁrmatory
study.
(1) Exploring safety and efﬁcacy
It is possible to infer the safe and effective dosage for anti-
microbial agents from information such as the antimicrobial
activity of the drug in regard to various pathogenic microor-
ganisms, various measurements obtained from in vivo tests
on small animals, the results of in vivo studies of pharmaco-
kinetics, and information on similar drugs.
Studies in this category aim to examine whether the dos-
age that has been established on the basis of such informa-
tion is appropriate.
Patients are excluded from these studies if they suffer
from severe underlying diseases or take many types of
medications because it is difﬁcult to assess the safety and
clinical underlying efﬁcacy of the investigational product
from these patients. In principle, the patients selected
for the study are relatively similar. All patients are observed
carefully. It is important to endeavor to isolate and
identify the pathogenic bacteria. It is also important to un-
derstand the relationship between the sensitivity of the bac-
teria to the drug and the clinical/microbiological efﬁcacy of
the investigational product.
Subjects are selected from patients with upper respira-
tory tract infections, pneumonia or secondary infection of a
chronic respiratory illness. All subjects are selected in
accordance with the characteristics of the investigational
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product. Subjects must be between 16 and 79 years of
age.
(2) Verifying recommended clinical dosage
Studies in this category may be conducted to conﬁrm the
safety of the estimated maximum clinical dosage. The safety
of the estimated maximum clinical dosage is the primarily
important aspect of this category for two reasons. Firstly, it
is ethically unacceptable to set up a group of subjects who
do not suffer from indications, because not only is clinical
efﬁcacy not likely to be observed, but it may also cause
harm as antimicrobial agents are designed to treat acute
illnesses. Secondly, the difference in dosage between the
two groups is small, and it is therefore difﬁcult to see the
difference in efﬁcacy between the groups. The dosage ad-
ministered to a low-dosage group is the recommended clini-
cal dosage that is anticipated to exert sufﬁcient efﬁcacy
because administration of inadequate (too low) dosage of
antimicrobial agents may decrease the sensitivity of the
pathogenic microorganisms to the drug. The dosage admin-
istered to a high-dosage group is usually double the recom-
mended clinical dosage, and is regarded as the estimated
maximum clinical dosage.
If there is a signiﬁcant difference between the two groups
in regard to efﬁcacy (clinical efﬁcacy and microbiological
efﬁcacy) and/or safety, it is necessary to examine the valid-
ity of the recommended clinical dosage in the conﬁrmatory
study.
Subjects are selected from patients with upper respiratory
tract infections, pneumonia or secondary infection of a
chronic respiratory illness. All subjects are selected in ac-
cordance with the characteristics of the investigational
product. Subjects must be between 16 and 79 years of age.
(3) Exploring clinical characteristics
Studies in this category aim to explore the clinically advan-
tageous characteristics of the investigational product. The
investigational product will be evaluated on the basis of the
efﬁcacy variables that were established from the viewpoint
of clinical beneﬁt.
Efﬁcacy (e.g. bacteria eradication rate, clinical efﬁcacy
for patients with infections due to unidentiﬁed pathogenic
bacteria, acquired resistance, efﬁcacy in regard to resistant
bacteria, and the characteristics of bacteria that emerge
after administration), speed of improvement in clinical con-
ditions (time required for symptoms and ﬁnding to im-
prove), compliance and safety (adverse drug reactions and
abnormal laboratory test values) are evaluated.
Subjects are selected from patients with upper respira-
tory tract infections, pneumonia or secondary infection of
a chronic respiratory illness. All subjects are selected in
accordance with the characteristics of the investigational
product. Subjects must be between 16 and 79 years of age.
3. Conﬁrmatory studies (mainly in phase III clinical trials)
The objective of these studies is to conﬁrm the clinical
beneﬁts.
In other words, these studies are conducted to verify that
the investigational product is safe and effective for the
treatment of the target indications. It is necessary to envis-
age patient-types to whom the investigational product will
be administered when it is marketed, and to conduct the
study by including these types of patients. In some cases, the
study is planned to examine the use of the investigational
product with concomitant drugs.
(1) Verifying non-inferiority or superiority of efﬁcacy (Con-
trolled studies: double-blind or open label)
Studies in this category aim to verify the safety and efﬁcacy
of the investigational product by comparing it with pre-
existing antimicrobial agents.
Subjects are selected from patients with acute tonsillitis,
pneumonia or secondary infection of chronic respiratory
illness. Subjects are selected in accordance with the charac-
teristics of the investigational product. Control drugs are
selected from marketed antimicrobial agents (regardless
of type) for which the results of clinical evaluations have
already been established. Control drugs are selected in ac-
cordance with the characteristics of the investigational
product and indications to be studied. Subjects must be
between 16 and 79 years of age.
In some cases, controlled studies with two investigational
product groups (a recommended clinical dosage group and
a maximum dosage group) and control group are conducted
in order to conﬁrm whether recommended clinical dosage
of the investigational product is safe and exerts maximum
efﬁcacy.
(2) Conﬁrming indications [expanding the range of
indications] (General study: Open label study)
Studies in this category determine the indications and bac-
teria to be treated. These studies aim to expand the range of
indications and obtain further information in regard to
safety and efﬁcacy.
The studies conﬁrm the safety and efﬁcacy toward indi-
cations that have not yet been tested in controlled studies.
Subjects are selected from patients with upper respiratory
tract infections, acute thoracic empyema or diffuse pan-
bronchiolitis. Subjects are selected in accordance with the
characteristics of the investigational product. Subjects must
be 16 years or older.
4. Therapeutic use (primarily phase IV in clinical trials)
These studies aim to collect further information regarding
appropriate usage of the investigational product when it is
marketed.
(1) Drug Use Investigation
The pharmaceutical company that manufactures the inves-
tigational product conducts this investigation in order to
collect information on adverse drug reactions (categorized
by indication), quality, efﬁcacy, safety and appropriate use.
In collecting this information, the company does not set
selection criteria for subjects.
(2) Special Investigation
The subjects in this investigation are patients who were
excluded from the pre-approval clinical trials on the
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grounds that they had a clinically special background (e.g.
children, elderly people, pregnant/parturient women and
patients with hepatic/renal dysfunction, bacteriological
sensitivity in post-marketing studies).
(3) Post-marketing studies
This is conducted, in compliance with GCP, in order to
examine the issues that were not clariﬁed during pre-
approval clinical trials, to verify information regarding
appropriate use that was obtained from the drug use
and special investigations, or to collect further information
that has not been obtained in clinical consultations.
In post-marketing studies for antimicrobial agents, it is
important to continue to examine drug sensitivity, as well as
efﬁcacy and safety, and to compare these results with results
obtained prior to approval of the investigational product. It
is also necessary to continue examination of interactions
with concomitant drugs.
IV Consideration for the Characteristics of the
Investigational Product and Administration Route
It is difﬁcult to prepare one protocol that can be applied to
all antimicrobial agents because they have different antimi-
crobial activities, different absorption, excretion and me-
tabolism characteristics, different administration routes,
and different indications. It is important for the protocol to
document the important points to which attention should be
paid in order to utilize the characteristics of the investiga-
tional product and evaluate clinical trials safely and objec-
tively. Existing antimicrobial agents are classiﬁed according
to their structure and the mechanism of their actions. In
addition, adverse drug reactions and drug interactions that
are typical of each type of antimicrobial agent have been
conﬁrmed. It is essential to examine these facts and check
the category of the investigational product in order to estab-
lish appropriate inclusion/exclusion criteria and test param-
eters. If the investigational product belongs to a new
category, it is necessary to establish these settings on the
basis of various fundamental data.
It is not uncommon to have different efﬁcacy and safety
criteria for different microbial agents due to clinical trial
types and available data in these trials. Therefore, when
selecting the efﬁcacy and safety criteria, it is necessary to
comprehensively consider the characteristics of the investi-
gational product, available data and the objectives of the
clinical trial.
1. Important points in the development of -lactam
antimicrobial agents
-lactam antimicrobial agents contain a -lactam ring in
their structure. They demonstrate their antimicrobial activ-
ity by binding to penicillin binding protein (PBP), an en-
zyme that synthesizes the walls of the bacteria cells, and
thereby inhibiting cell-wall synthesis. In Japan, many phar-
maceutical products of this type (primarily cephem antimi-
crobial agents) have been developed and administered
clinically because they have excellent selective toxicity and
a strong antimicrobial activity. Many researches on drugs in
this category were conducted in regard to their antimicro-
bial spectrum (which reﬂects their chemical structures),
antimicrobial activities, tissue penetration, characteristic
adverse drug reactions, and interactions with metabolic en-
zymes, even -lactamase inhibitors. Therefore, in develop-
ing new antimicrobial agents in this category, it is most
important that they are distinguishable from existing -
lactam antimicrobial agents.
There is need for new cephem antimicrobial agents that
have a stable chemical structure against ESBLS and/or
stronger antimicrobial activities against S. aureus and P.
aeruginosa. There is also need for new drugs that have
excellent tissue penetration.
From a chemical structural point of view, a more stable
structure is a desirable characteristic for new carbapenem
antimicrobial agents. From a microbiological point of view,
it is desirable for new drugs to provide an anti-MRSA activ-
ity equivalent to vancomycin (VCM) and to have increased
binding afﬁnity for PBP2 prime, and increased antimicro-
bial activities against Pseudomonas aeruginosa. In addition,
it is expected that long-acting (prolonged half-life in blood)
preparations with Class B -lactamase inhibitors will be
developed. It is also expected that the oral form of
carbapenem antimicrobial agents with a high level of
bioavailability will be developed.
The important issues in regard to safety have largely
changed over time and vary in accordance with type, such as
penicillins, cephem antimicrobial agents or carbapenem
antimicrobial agents. The primary concerns in regard to
adverse drug reactions include anaphylactic shock, renal
damage due to drug interactions, “Antabuse” action due to
N-methylthiotetrazole group, coagulopathy and damage to
the central nervous system due to the inhibition of γ-
aminobutyric acid (GABA) receptors. There is a need for
carbapenem antimicrobial agents that have attenuated
nephrotoxicity and/or are less toxic to the central nervous
system.
It is well established that penicillins and cephem antimi-
crobial agents are the safest -lactam antimicrobial agents,
which have a long history. It is necessary to carefully inves-
tigate the safety of new -lactam antimicrobial agents, espe-
cially those with new chemical structures or additional
group structures, without restricting safety considerations
to the safety characteristics of existing drugs.
2. Macrolides
Macrolides have a lactone ring (1216-membered ring).
They demonstrate their antimicrobial activity by binding
with the 50S subunit of the 70S bacterial ribosome, and
thereby inhibiting protein synthesis. They have a broad an-
timicrobial spectrum and are effective against anaerobes
(for which lincomycin is ineffective), and pathogenic micro-
organisms of atypical pneumonia (for which -lactam
antimicrobial agents are ineffective). They also have an
inhibitory action on the formation of bioﬁlm and bacteria-
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based enzymes and modulating effects on immune re-
sponses in the living body. A new macrolide that has a 15-
membered ring and high intracellular penetration has
recently been developed. This preparation demonstrates
non-inferior efﬁcacy compared to existing macrolides with a
14 or 16-membered ring. A new macrolide with an antimi-
crobial activity against resistant bacteria such as PRSP is
needed. Ketolide, a new macrolide under development,
does provide this type of action and is beginning to receive
recognition.
It is more likely that macrolides with new chemical struc-
tures will be developed in the future. This means that new
preparations will have new antimicrobial activities as well as
different in vivo reactions. It is therefore necessary to con-
duct investigations in regard to drug efﬁcacy from multiple
directions.
In regard to safety, macrolides sometimes cause pro-
longed QT and increase the actions of muscle relaxants
when used simultaneously. It is necessary to carefully inves-
tigate the safety of new macrolides, especially those with
new chemical structures or additional group structures,
without restricting safety considerations to the safety char-
acteristics of existing drugs.
3. Quinolones
Quinolone antimicrobial agents inhibit DNA synthesis of
bacteria by acting on DNA gyrase A, a type of topoiso-
merase that is necessary for DNA synthesis. Quinolones
rapidly became common drugs in clinical situations because
of their excellent bactericidal effects and intracellular pen-
etration. New quinolones have a greater level of tissue
penetration than ordinary quinolones, thus expanding the
range of indications that can be treated. In developing
quinolones, it is important to note that drug-resistant bacte-
ria and acquired resistance should be fully investigated so
that new quinolones with antimicrobial activities against
resistant bacteria can be developed. It is expected that
quinolones that have an antimicrobial activity against VRE,
MRSA, PRSP, ESBLS, tubercle bacillus, Pseudomonas
aeruginosa and anaerobes, and increased effects on bio-
ﬁlm will be developed, as well as an injection-type will be
developed.
In regard to safety, the incidence and types of adverse
drug reactions increased as the number of patients to whom
quinolones were prescribed increased. Arthropathia, drug
interactions, photosensitivity reactions and central nervous
system related symptoms are already known to be adverse
drug reactions. It is necessary to pay attention to hepatic
dysfunction and prolonged QT as potential adverse drug
reactions. Improved quinolones are needed with respect to
adverse drug reactions.
When looking back over the history of the rapid devel-
opment and marketing of quinolones, it can be said that it is
necessary to determine points that differentiate the devel-
opmental drugs from the pre-existing drugs, and consider
how we wish to apply the new drugs to treat indications
when they are marketed. These issues should be considered
in the early stages of development.
4. Aminoglycosides
Aminoglycosides have sugar chains and amino groups as
substituents in their structure. They exert an antimicrobial
activity by combining with bacterial ribosomes and thereby
inhibit their protein synthesis. They have bactericidal ef-
fects on anaerobes, acid-fast bacteria, and general bacteria,
with the exception of atypical bacteria. It is necessary to put
safety ﬁrst when developing aminoglycosides, as they have a
neuroleptic action and may cause damage to the kidneys
and/or ears. In particular, if patients are newborn babies,
elderly people or patients with renal dysfunction, it is neces-
sary to monitor drug concentrations in the blood in order to
maintain concentrations within the safe ranges. It is possible
to discover new advantageous characteristics during the
development of aminoglycosides because these drugs inﬂu-
ence the frequency of the emergence of resistant bacteria.
5. Tetracyclines
Tetracyclines consist of four rings with various substituents.
They demonstrate an antimicrobial activity by binding with
the 30S subunit of the 70S bacterial ribosome, and thereby
inhibit protein synthesis. They have a broad antimicrobial
spectrum (e.g. general bacteria, atypical bacteria, Rickettsia
and non-fermentative bacteria). In regard to safety, it is
necessary to pay careful attention to hepatic dysfunction.
Some tetracyclines have antimicrobial activities against
MRSA. New tetracyclines with stronger anti-MRSA
activities are necessary to tackle the problems of resistant
bacteria.
6. Other antimicrobial agents and important issues in the
development of antimicrobial agents in the future
To date, glycopeptide antimicrobial agents, polypeptide
antimicrobial agents, TMP/SMX, fosfomycin and mupiro-
cin have been developed as new antimicrobial agents. They
have new chemical structures, various mechanisms of ac-
tion, and characteristic antimicrobial spectrums; and thus
are distinguishable them from the existing antimicrobial
agents.
At present, great attention is being paid to oxazolidi-
nones that have proven antimicrobial activities against
VRE, and streptogramins, both of which are under develop-
ment. Development of new antimicrobial agents that are
effective against various resistant bacteria is expected.
7. Important issues in the development of oral drugs
and injections
It is important to establish a method of conﬁrming
that patients are complying with dosage and administration,
and to communicate safety measures to patients in a way
that is easy to understand. In order to do so, it is necessary
to prepare a full range of clinical trial support tools in
advance.
It has become recent practice to conduct low-dose stud-
ies for oral antimicrobial drugs. However, if a subject in this
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type of study is suffering from a respiratory tract illness, it is
necessary to establish the appropriate dosage and adminis-
tration from basic data in order to secure a sufﬁcient level of
drug concentration in the blood and tissue for drugs to exert
antimicrobial activities.
The subjects in clinical trials for injections are usually
inpatients, such as patients with severe infections and eld-
erly people. Great consideration needs to be given to con-
comitant drugs and therapies, as well as resolvents. In some
cases, it is necessary to consider possible concomitant drugs
from the beginning of the development of injections, and
conduct clinical trials accordingly.
8. Important issues in the development of antimicrobial
agents in the future
In the future, when developing antimicrobial agents it will
be necessary to consider the background of subjects, the
medical environments in which the investigational product
will be used, and the socioeconomic conditions.
The requisite characteristics of new antimicrobial agents
include selective toxicity, strong antimicrobial activities,
characteristic antimicrobial spectrums, tissue penetration
and cell penetration. It is also necessary for new drugs to
have metabolic pathways that will not be inﬂuenced by
hepatic/renal functions. In order to provide antimicrobial
agents in good time, it is necessary to have clear objectives
for the clinical trial and design it very well by considering:
the results of clinical trials conducted in foreign countries;
demographics, such as subject population; and changes
in the medical environment, such as medical insurance
schemes.
In regard to safety, it is necessary to develop new antimi-
crobial agents that have fewer interactions with other drugs,
including metabolic enzymes. In each case, it is necessary
establish a method to prove that adverse drug reactions due
to drug interactions can be easily treated.
V Outline of Clinical Trial Protocol
The following points should be kept in mind when using this
protocol model. The sponsor of a trial is expected to draw
up the protocol based on all components of this model.
However, it should be noted that this model is merely an
example that demonstrates how to prepare a protocol and
the style that should be used. In other words, the indications
studied, the observation and test parameters, and the pri-
mary efﬁcacy and safety variable(s) should be set in accor-
dance with the characteristics of the investigational product
and the purpose of the development of the drug. Compo-
nents should not be limited to those shown in this model.
The sponsor may follow their own standard operating pro-
cedure (SOP) as long as the protocol satisﬁes the compul-
sory components of this model. Table (1) is an example of a
protocol design of different phase clinical trials and their
respective objectives. If the data is to be combined with
data obtained overseas (bridging), the sponsor may wish to
adopt the protocol-style of the country from which data was
obtained. Nonetheless, the Bridging Study Committee has
set out a guideline for bridging data, and the sponsor should
follow the guideline. In this model, the points that should be
kept in mind when preparing a protocol have been written
within speech balloons. The most important points are
that the protocol reﬂects the development strategy of the
investigational product, and that the strategy is consistent
throughout all phases of the clinical trial. However, it is
scientiﬁc to draw up a different protocol with a new devel-
opment strategy based on ﬁndings from the results of clini-
cal trials.
Table 1. Protocol designs based on different phase clinical trials and their objectives
Phase Early phase II Late phase II Phase III
Objective Safety and Conﬁrmation of Exploration Investigation of Conﬁrmation of
efﬁcacy study the clinically of clinical non-inferior or indication
recommended characteristics superior efﬁcacy
dosage and safety
Design Exploratory Exploratory Exploratory Conﬁrmatory Conﬁrmatory
Non-comparative Comparative Non-comparative Comparative Non-comparative
or comparative
Open Open or double- Open or double- Open or double- Open
blind blind blind
Indications Acute respiratory 1) Tonsillitis Acute respiratory 1) Tonsillitis Acute respiratory
studied tract infections 2) Pneumonia tract infections 2) Pneumonia tract infections,
Pneumonia or secondary Pneumonia and/or secondary thoracic empyema,
Secondary infection of Secondary infection of DPB, etc.
infection of chronic respiratory infection of chronic respiratory
chronic respiratory illness chronic respiratory tract infections
illness illness
Age of subjects 1674 years old 1679 years old 1679 years old 1679 years old 16 years or older
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VI Appendix/Outline of Clinical Trial Protocol
Exploratory/Conﬁrmatory Phase X Clinical Trial of JSC-0X (name of the investigational product) for the Treatment of
Acute Respiratory Tract Infections, Pneumonia and Secondary Infections of Chronic Respiratory Illnesses
Clinical Trial Protocol
Sponsor: JSC Co., Ltd.
Designs and the indications studied for clinical trials should be determined in accor-
dance with the characteristics of the investigational product and the objective of the
trial.
If the indication is only upper respiratory tract infections due to the characteristics of
the investigational product, the indication to be studied in the comparative test will be
tonsillitis.
List of abbreviations and terms






Minimum Inhibitory Concentration MIC
Methicillin-resistant Staphylococcus aureus MRSA
Penicillin-resistant Streptococcus pneumoniae PRSP
Laboratory parameters
Full wording Abbreviation Unit
(1) Hematological examination
Red blood cell RBC (104/mm3)
Hemoglobin Hb (g/dL)
Hematocrit HCT (%)
White blood cell WBC (/mm3)
(2) Serum biochemical examination
Glutamic oxaloacetic transaminase GOT (U/L)
Glutamic pyruvic transaminase GPT (U/L)
γ-Glutamyl transpeptidase γ-GTP (U/L)
Alkaline phosphatase ALP (U/L)
(3) Testing for inﬂammation
C-reactive protein CRP (mg/dL)
Erythrocyte sedimentation rate ESR (mm/hr)
(4) Blood gas analysis
Partial pressure of oxygen PaO2 (Torr)
Partial pressure of carbon dioxide PaCO2 (Torr)
Protocol No.: JSC-0X RTI
Date of composition: X, X, 200X
Conﬁdentiality The information contained in this protocol
is reserved by JSC Co., Ltd., and is provided only to medical
institutions that wish to participate in this trial, the principal
investigator, subinvestigators, clinical trial staff, and the in-
stitutional review boards. As such, the information may not
be disclosed to third parties without permission from JSC
Co., Ltd., with the exception of the subjects who consent to
participate in the trial.
The following components must be included in the protocol.
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I. Protocol Overview
1.1 Objective of the trial
To investigate/verify XXXX of JSC-0X (Xmg) with respect
to clinical efﬁcacy/microbiological efﬁcacy (administration
period: 7 days or less) in patients with mild/moderate/severe
acute respiratory tract infections, pneumonia, or secondary
infection of chronic respiratory illness. The trial is a multi-
center trial. Adverse drug reactions and abnormal changes
in laboratory parameters will also be examined.
1.2 Subjects
1.2.1 Indications studied
The indications studied are the following mild/moderate/
severe respiratory tract infections that are (possibly) caused
by microbes sensitive to JSC-0X.
1) Acute respiratory tract infections
2) Pneumonia, pulmonary abscess and acute thoracic
empyema
3) Secondary infection of chronic respiratory illness
1.2.2 Inclusion criteria
Patients who meet the following criteria will be included in
this trial.
1) Outpatients/inpatients (male/female) who are over
XX and below XX years of age on the day of
consent.
2) Patients who can express subjective symptoms, and who
consent to participate in the clinical trial of their own
volition.
3) Patients whose diseases have been judged as mild/
moderate/severe by the principal investigator or sub-
investigators on the basis of the inclusion criteria for
clinical evaluation and the severity criteria for infections
set down in Clinical Evaluation Methods for New Anti-
microbial Agents for the Treatment of Respiratory
Tract Infections (Japanese Society of Chemotherapy).1)
4) Other criteria that have been established in accordance
with the characteristics of the investigational product.
1.2.3 Exclusion criteria
Patients will be excluded from this trial on the basis of the
following criteria.
1) Patients whose diseases have been judged as severe
by the principal investigator or subinvestigators on the
basis of the severity criteria for infections set down in
Clinical Evaluation Methods for New Antimicrobial
Agents for the Treatment of Respiratory Tract Infec-
tions (Japanese Society of Chemotherapy).1
2) Patients suffering severe liver or kidney dysfunction.
3) Patients who have been receiving other antimicrobial
agents and whose medical conditions are improving.
4) Female patients who are known to be, or suspected to
be, pregnant, or lactating.
5) Patients who have participated in other clinical trials of
drugs, either within the past one month, or in the case
that the period since the last administration of other
clinical trial drugs is less than 5 times the half-life of
those drugs.
6) Patients suffering from an infection caused by a single
type of microbe that is resistant to JSC-0X, and for
which it is difﬁcult to expect the drug to exhibit efﬁcacy.
7) Patients who have participated in a previous clinical trial
of this drug.
8) Other criteria based on the characteristics of the investi-
gational product.
If patients have been receiving drugs that interact with the investiga-
tional product, or long-acting antimicrobial agents that may inﬂuence
evaluation of the efﬁcacy of the investigational product, criteria appro-
priate to such drugs should be established.
1.3 Investigational product
1.3.1 Name of the investigational product
Code: JSC-0X
1.3.2 Volume of the active ingredient, and dosage form
JSC-0X is a tablet/capsule/ample that contains XXmg
(titer).
The preparation contains XXXX as an inactive ingredient.
1.3.3 Packaging of the investigational product
One JSC-0X tablet/capsule/ample is packaged in XXX.
1.4 Clinical trial design
1.4.1 Clinical trial design
This is an open/double-blind exploratory/conﬁrmatory
multicenter trial.
1.4.2 Efﬁcacy and safety valuables
1) Primary efﬁcacy/safety valuable(s)
(e.g.) Clinical efﬁcacy and microbiological efﬁcacy (at
the time of the completion of the trial)
2) Secondary efﬁcacy/safety valuable(s)
(e.g.) Microbiological efﬁcacy for each type of causal
bacteria
Adverse drug reactions and abnormal changes in labora-
tory parameters
1.4.3 Dosage and administrations
Once consent has been obtained, the principal investigator
or subinvestigators will administer the investigational prod-
uct orally/intravenously in accordance with the dosage and
administrations shown in the table below.
Volume per dose Frequency (per day)
 mg X times
H17009 mg Y times
1.4.4 Administration period (e.g. 7-day administration
period)
Administration will generally be seven days (168 hours)
(possibly eight calendar days). However, administration
will be terminated prematurely or discontinued within this
period if the Objective of the therapy is achieved or the
patient meets the discontinuation criteria described below.
If a longer administration period is necessary, the drug may
be administered for up to 14 days (or 15 calendar days).
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1.4.5 Clinical trial period
From XX/XX/XX to XX/XX/XX
1.4.6 Target population
XXX cases
1.4.7 Pretreatment and concomitant therapies
The following drugs and therapies are prohibited for use
in conjunction with the investigational product. However,
when these drugs or therapies are deemed necessary for the
beneﬁt of the subject, administration of the investigational
product will be discontinued. If it is found that the subject
is receiving these drugs or therapies, administration of the
investigational product will be discontinued.
1) Other oral antimicrobial agents or antimicrobial
injections
2) Human immunoglobulin preparations
3) Colony-stimulating factor preparations (G-CSF etc.)
4) Adrenocorticosteroids (equivalent to 10mg or more of
prednisolone per day by means of inhalation or general
administration)
5) Continuous administration of antipyretic analgesics
(Occasional use is acceptable.)
6) Other drugs and medical instruments under
development
7) Bronchial washing
8) Other drugs that should be prohibited due to the charac-
teristics of the investigational product
1.5 Observation, test and investigation parameters
1.5.1 Observation, test and investigation parameters
Observations and tests will be conducted in accordance with
the following chart.
1.5.2 Flow chart
This clinical trial will be conducted in the following se-
quence.
1) Conﬁrm that subjects fulﬁll the inclusion criteria, and
that they should not be excluded on the basis of the
exclusion criteria. All subjects who are informed of the
clinical trial will be recorded on the Screening List,
regardless of whether they consent to participate.
2) The pre-administration examinations that are necessary
for the trial will be conducted following the obtainment
of consent.
3) The investigational product will be administered in ac-
cordance with the “Dosage and administrations of the
investigational product”. Subjects receive the necessary
instructions.
4) Planned observations and tests will be conducted on a
speciﬁed day. Results for each item will be evaluated and
assessed.
5) The principal investigator or subinvestigators will check
for any adverse events that have occurred between the
day of commencement of administration of the investiga-
tional product and the ﬁnal observation day. If adverse
events have occurred during this period, the principal
investigator or subinvestigators will conduct a follow-up.
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1.6 Efﬁcacy and safety variables and evaluation method
1.6.1 Efﬁcacy
1) Clinical efﬁcacy of the investigational product three days
after the commencement of administration, and at the
time of completion of administration
The principal investigator or subinvestigators will assess
clinical efﬁcacy on the basis of the clinical efﬁcacy evalu-
ation criteria in Clinical Evaluation Methods for New
Antimicrobial Agents for the Treatment of Respiratory
Tract Infections (Japanese Society of Chemotherapy).1)
2) Microbiological efﬁcacy at the completion of
administration
The principal investigator or subinvestigators will assess
clinical efﬁcacy on the basis of the microbiological efﬁ-
cacy evaluation criteria in Clinical Evaluation Methods
for New Antimicrobial Agents for the Treatment of
Respiratory Tract Infections (Japanese Society of
Chemotherapy).1)
1.6.2 Safety
1) Adverse drug reactions
Adverse drug reactions will be assessed on the basis of
Assessment Criteria for Adverse Drug Reactions and
Abnormal Changes in Laboratory Parameters in Clini-
cal Trials for Antimicrobial Agents (Japanese Society of
Chemotherapy).2)
2) Abnormal changes in laboratory parameters
Abnormal changes in laboratory parameters will be as-
sessed on the basis of Assessment Criteria for Adverse
Drug Reactions and Abnormal Changes in Laboratory
Parameters in Clinical Trials for Antimicrobial Agents
(Japanese Society of Chemotherapy).2)
II. Protocol
1. Background and history
The following points should be documented in accordance
with the characteristics of the investigational product.
Origin and history of development
Name of the investigational product and relevant
explanations
Summary of clinically important ﬁndings obtained in
non-clinical trials and previous clinical trials
Summary of the known and potential risks and beneﬁts
to human subjects
Description of population, objective and method, and
justiﬁcation for this clinical trial
References (guidelines etc.)
2. Good clinical practice (GCP)
This clinical trial will be conducted in accordance with: 1)
Declaration of Helsinki (a statement of ethical principles to
provide guidance to physicians and other participants in
medical research involving human subjects); 2) Clause 3,
Article 14, and Clause 2, Article 80 of the Pharmaceutical
Affairs Law, as well as Ordinance No. 28 of the Ministry of
Health and Welfare, Guideline for Good Clinical Practice
(which came into force on April 1, 1997).
The principal investigators, in association with the spon-
sor, agree to the contents of the protocol and case report
forms. The principal investigators also pledges, prior to con-
ducting the clinical trial, that he or she will comply with the
protocol and case report forms in all respects.
3. Administrative structure of the clinical trial
This clinical trial is planned and conducted by the adminis-




Each member and their role should be described.
3.1.3 Medical expert
3.1.4 Monitor
3.1.5 Person responsible for (or in charge of) quality
assurance
3.1.6 Person responsible for (or in charge of) data
management




3.1.10 Person responsible for (or in charge of) management
of the investigational product (drug management ofﬁcer)
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3.2 Contract research organization
3.3 Laboratory to conduct laboratory testing
3.4 Laboratory to conduct microbiological testing
3.5 Principal investigators
3.6 Efﬁcacy and safety evaluation committee (independent
data-monitoring committee)
3.7 Coordinating investigator and coordinating committee
3.8 Clinical trial sites (medical institution)
3.9 Person responsible for assigning the investigational
product
3.10 Person responsible for testing the investigational
product
4. Objective of the trial
4.1 Objective of the trial
To investigate/verify XXXXX of JSC-0X (Xmg) with
respect to clinical efﬁcacy/microbiological efﬁcacy
(administration period: 7 days or less) in patients with
mild/moderate/severe acute respiratory tract infections,
pneumonia, or secondary infection of chronic respiratory
illness. The trial is a multicenter trial. Adverse drug reac-
tions and abnormal changes in laboratory parameters will
also be examined.
The speciﬁc efﬁcacy or safety variables (primary/secondary variables)
that clarify the clinical characteristics of the investigational product
should be described here as the target to be investigated or veriﬁed.
Targets may vary in accordance with the phase and design of trials.
4.2 Type of trial





The indications studied or the bacteria treated should be set in accor-
dance with the characteristics of the investigational product or objec-
tive of the trial. For example: atypical pneumonia may be set as the
indication studied in accordance with the characteristics of a drug;
panbronchiolitis may be set as the indication studied in accordance
with the objective of the trial; or, in order to distinguish pneumonia
that is caused by community acquired infection from pneumonia that is
caused by hospital acquired infection, one of the two types of pneumo-
nia would be set as the indication studied.
The indications to be studied are the following mild/moder-
ate/severe respiratory tract infections that are (possibly)
caused by microbes sensitive to JSC-0X.
1) Acute respiratory tract infections
Upper respiratory tract infections (acute tonsillitis, acute
pharyngitis and acute laryngopharyngitis) and acute bro-
nchitis, peritonsillar abscess and retropharyngeal
abscess
2) Pneumonia, pulmonary abscess and acute thoracic
empyema
3) Secondary infection of chronic respiratory illness
Chronic bronchitis, bronchiectasis, pulmonary emphy-
sema, bronchial asthma, pulmonary ﬁbrosis and inveter-
ate pulmonary tuberculous
5.2 Inclusion criteria
Criteria should be set in accordance with the objective of the trial.
Patients who meet the following criteria will be included in
this trial.
Refer to the agreements for each phase.
1) Outpatients/inpatients (male/female) who are over XX
and below XX years of age on the day of consent.
2) Patients who can express subjective symptoms, and who
consent to participate in the clinical trial of their own
volition.
3) Patients whose diseases have been judged as mild/mod-
erate/severe by the principal investigator or subinvesti-
gators on the basis of the inclusion criteria for clinical
evaluation and the severity criteria for infections set
down in Clinical Evaluation Methods for New Antimi-
crobial Agents for the Treatment of Respiratory Tract
Infections (Japanese Society of Chemotherapy).
4) Other criteria that have been established in accordance with the
characteristics of the investigational product.
5.3 Exclusion criteria
Patients will be excluded from this trial on the basis of the
following criteria.
1) Patients whose diseases have been judged as severe on
the basis of the severity criteria for infections set down
in Clinical Evaluation Methods for New Antimicrobial
Agents for the Treatment of Respiratory Tract Infec-
tions (Japanese Society of Chemotherapy).
2) Patients suffering severe liver or kidney dysfunction.
Criteria should be set for each characteristic of the investigational
product. When doing so, criteria should be described concretely (e.g.
using grades in Severity Categorization Criteria for the Adverse Drug
Reaction of Pharmaceutical Products. Notice No. 80 issued by Safety
Division, Pharmaceutical Affairs Bureau, Ministry of Health and
Welfare.
3) Patients who have been receiving other antimicrobial
agents and whose medical conditions are improving.
4) Female patients who are known to be, or suspected to
be, pregnant, or lactating.
An explanation of pregnancy testing procedures and guidance in the
use of contraceptives should be included if the drug is suspected to be
reproductively or developmentally toxic.
5) Patients who have participated in other clinical trials of
drugs, either within the past one month, or in the case
that the period since the last administration of other
clinical trial drugs is less than 5 times the half-life of
those drugs.
6) Patients suffering from an infection caused by a single
type of microbe that is resistant to JSC-0X, and for
which it is difﬁcult to expect the drug to exhibit efﬁcacy.
7) Patients who have participated in a previous clinical trial
of this drug.
8) Other criteria based on the characteristics of the investi-
gational product.
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If patients have been receiving drugs that interact with the investiga-
tional product, or long-acting antimicrobial agents that may inﬂuence
evaluation of the efﬁcacy of the investigational product, criteria appro-
priate to such drugs should be established.
5.4 Subject enrollment list
The principal investigator will prepare a list of the subjects
who have consented to participate in this trial. The list will
include the initials, sex, date of consent and ID codes for
each subject.
6. Patient information and consent
6.1 The consent form and written information
The principal investigator(s), in association with the spon-
sor, will prepare, or amend if necessary, the consent form
and any written information in order to obtain consent from
subjects to participate in the clinical trial. These documents
will be supplied to the sponsor to obtain approval from the
institutional review board(s) of the trial site(s).
6.2 The content of the written information
Refer to a sample prepared by the informed consent composition
committee.
The following points will be included in the written infor-
mation, which includes any amended documents. Further-
more, the principal investigator or subinvestigators should
provide a full explanation of these points when obtaining
consent from the subjects.
1) The trial involves research
2) The objective of the trial
3) The method of the trial (aspects of the trial that are
experimental, inclusion criteria and probability of
treatment assignment)
4) The expected duration of each subject’s participation in
the trial
5) The approximate number of subjects involved in the
trial
6) The reasonably foreseeable clinical beneﬁts, risks or
inconveniences to each subject (If there are no in-
tended clinical beneﬁts to a subject, the subject should
be made aware of this fact.)
7) The alternative treatment that may be available to each
subject, and their important potential beneﬁts and risks
8) Compensation and treatment available for subjects in
the event of trial-related injury
9) Each subject’s participation in the trial is voluntary and
any subject may refuse to participate, or may withdraw
from the trial, at any time, without penalty or loss
of beneﬁts to which the subject would otherwise be
entitled.
10) Each subject will be informed, in a timely manner, if
information becomes available that may be relevant to
their willingness to continue to participate in the trial.
11) The conditions that apply to a subject withdrawing
from the trial
(If a subject is withdrawn from the trial, reasons will be
provided.)
12) The monitor, the auditor, the institutional review
board, and the regulatory authority will be granted di-
rect access to subjects’ original medical records, but will
not violate the conﬁdentiality of any subject. By signing
the written informed consent form, the subject is autho-
rizing such access.
13) The identity of all subjects will remain conﬁdential,
even though the results of the trial may be published.
14) Anticipated expenses (if any)
15) Anticipated payment (if any) and how the amount is
determined
16) The name, position and contact number/address of the
principal investigator or subinvestigators
17) The person of the trial site who can be contacted for
further information regarding the trial and the rights of
trial subjects, and the person who should be contacted
in the event of trial-related injury
18) Each subject’s responsibilities
6.3 Timing and method of obtaining consent
If consent by a subject’s legally acceptable representative is necessary,
the method by which consent is obtained should be documented.
Prior to the clinical trial, the principal investigator or
subinvestigators will use the consent form and other written
information to provide each subject with a full explanation
of the trial and the rights of subjects. The principal investi-
gator or subinvestigators will then obtain consent that is
freely given by each subject. (Each subject must print
their name, sign or stamp, and date the consent form.) The
principal investigator or subinvestigators will record, on
the subject-enrollment list, the names of each subject who
received an explanation of the trial. The physician (and
physician’s assistants) who provided the explanation will
print their names, sign or stamp, and date the consent form.
The principal investigator or subinvestigators will check
whether any subject is also under the care of another physi-
cian. If so, the subject’s participation in the trial will be
reported to the subject’s physician, on agreement with the
subject. The principal investigator or subinvestigators will
record on the case report form the date that the information
was sent to the subject’s physician.
The principal investigator, subinvestigators or trial staff
will provide each subject with a copy of the informed con-
sent form and the other written information. The originals
will be stored in a speciﬁed location at each trial site.
6.4 Important points in regard to obtaining informed
consent
The following points are regarded as important in obtaining
informed consent.
1) The principal investigator or subinvestigators should not
coerce or unduly inﬂuence any subject to participate or
to continue to participate in a trial.
2) Information should not contain any language that causes
any subject to waive or to appear to waive any legal
rights, or that releases or appears to release the investi-
gator, trial staff, the medical institution or the sponsor
from liability for negligence.
3) The language used in information should be as non-
technical as practicable and should be understandable to
the subject.
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6.5 Amending the consent form and written information
(adding new information)
If the sponsor obtains information that may be relevant to
any subject’s willingness to continue to participate in the
trial, the sponsor will promptly inform the head of each trial
site and the principal investigator in writing.
The principal investigator or subinvestigators will
promptly inform all subjects and ask each one whether they
wish to continue to participate in the trial. Consent will
need to be given again in the knowledge of the revised
information. Communication of the new information to
each subject should be documented. If a subject is an outpa-
tient, consent (with their printed name, signature/stamp,
and date) will need to be obtained at his/her next visit.
The principal investigator will, in a timely manner, revise
the consent form and written information based on the new
information that has become available, and then obtain
approval from the institutional review board.
7. Investigational product
7.1 Investigational product
7.1.1 Name of investigational product (Code)
JSC-0X




7.1.3 Dosage form and volume of active ingredient
JSC-0X is a XXXXXXX preparation that contains XXmg
(titer). The dosage form is a tablet/capsule/ample.
The preparation contains XXXX as an inactive
ingredient.
7.2 Packaging and labeling
Packaging: One JSC-0X tablet/capsule/ample is packaged
in a XXXXXXX that is stored in a pharmaceutical box
(white box, * cm  * cm  * cm). The following label will
appear on the box. The investigational product should be
stored at room-temperature/in a cool place/freezer. (Keep
away from light). Expiration date: XXXXXX, 200X.
ofﬁcer etc.) once the clinical trial contract has been con-
cluded with the institution. Delivery will be carried out by
the monitor. The drug management ofﬁcer will receive the
invoice, check the quantity and print his/her name on the
receipt and sign or stamp it.
7.4 Storage and management of the investigational product
The head of each medical institution will assign a drug
management ofﬁcer to store and manage the investigational
product. The drug management ofﬁcer etc. will store and
manage the investigational product in accordance with the
storage conditions stated in the “Instructions for handling
the investigational product”, which will be prepared by the
sponsor. The drug management ofﬁcer will also draw up the
investigational product handling record form in which pre-
scribed quantities and other relevant information will be
recorded.
The drug management ofﬁcer, the principal investigator,
subinvestigators and trial staff will handle the investiga-
tional product in accordance with the instructions for stor-
age. If the expiration date of the investigational product has
passed and it is necessary to replace the product with a new
batch, the sponsor will reclaim the unused portion of the
drug and replace it.
7.5 Reclaiming the investigational product
In reclaiming the investigational product, the sponsor will
check the quantities of used and unused portions of the
drug and issue a certiﬁcate of reclamation to the drug man-
agement ofﬁcer etc. The drug management ofﬁcer etc. will
print his/her name on the drug return form and sign/stamp
it. He/she will submit a copy of the investigational product
management record form to the sponsor.
7.6 Instructions for management of the investigational
product
The sponsor will prepare the “Instructions for handling the
investigational product” and submit these instructions to
the head(s) of the medical institution(s).
7.7 Analysis of the investigational product
A third party organization, or similar, will analyze the inves-
tigational product prior to supplying it to the drug manage-
ment ofﬁcer etc. in order to conﬁrm that the product
conforms to the set standards. The same examination will
be conducted by a third party organization at the comple-
tion of the trial.
8. Clinical trial design
8.1 Clinical trial design
8.1.1 Type of clinical trial
This is an open/double-blind exploratory/conﬁrmatory
multicenter trial.
8.1.2 Flow chart
This clinical trial will be conducted in the following se-
quence.
1) Conﬁrm that subjects fulﬁll the inclusion criteria, and
that they should not be excluded on the basis of the
7.3 Supplying the investigational product
The sponsor will deliver the investigational product directly
to the drug management ofﬁcer or person assigned by the
drug management ofﬁcer (hereinafter, drug management
301
exclusion criteria. Informed consent is obtained. All sub-
jects who are informed of the clinical trial will be re-
corded on the Screening List (Attachment 2), regardless
of whether or not they consent to participate.
2) The pre-administration examinations that are necessary
for the trial will be conducted following consent.
3) The investigational product will be administered in
accordance with “8.5 – Administration dosage and
method”.
For example, instruct subjects to take the drug within 30 minutes
following meals in the case of an oral drug. Provide a full explanation
and written instructions on how to take the drug for all subjects at the
time of consent.
4) Planned observations and tests will be conducted on a
speciﬁed day. Results for each item will be evaluated and
assessed.
5) The principal investigator or subinvestigators will
check for adverse events that have occurred between the
day of commencement of administration of the investi-
gational product and the ﬁnal observation day. If ad-
verse events have occurred during this period, the
principal investigator or subinvestigators will conduct
follow-up.
8.2 Randomization and blinding
In the case of comparative trials, it is necessary to include the following
documentation (8.2 and 8.3).
The XXXX method for randomization and blinding will be
used in order to minimize selection bias. The randomization
and blinding procedures will be documented.
8.3 Treatment assignment list, and composition and storage
of an emergency key code
The person responsible for assigning the investigational
product will randomize the group of subjects using the XXX
method in order to divide subjects into a JSC-0X group and
a control group. The investigational product will be as-
signed in accordance with the randomization method (e.g.
using the sequence of the assignment numbers of the drug/
placebo and sequence of the subject ID codes). The person
responsible for assigning the investigational product will
seal the treatment assignment list and store it safely and
attentively until the time of unsealing. The person respon-
sible for assigning the investigational product will make an
emergency key code and ensure that the code is broken
only in accordance with the decoding procedure that has
been speciﬁed.
8.4 Efﬁcacy and safety variables
8.4.1 Primary efﬁcacy and safety variables
Suitable primary efﬁcacy and safety variables should be set in accor-
dance with the characteristics of the investigational product and the
objective of the clinical trial.
1) Efﬁcacy
(1) Clinical efﬁcacy (at the time of completion of
administration)
The principal investigator or subinvestigators will as-
sess clinical efﬁcacy on the basis of the clinical efﬁcacy
evaluation criteria set down in Clinical Evaluation
Methods for New Antimicrobial Agents for the
Treatment of Respiratory Tract Infections (Japanese
Society of Chemotherapy).1)
(2) Microbiological efﬁcacy (at the completion of
administration)
The principal investigator or subinvestigators will as-
sess clinical efﬁcacy on the basis of the microbiological
efﬁcacy evaluation criteria set down in Clinical Evalua-
tion Methods for New Antimicrobial Agents for the
Treatment of Respiratory Tract Infections (Japanese
Society of Chemotherapy).1)
2) Safety
(1) Adverse drug reactions
Adverse drug reactions will be assessed by referring
to Assessment Criteria for Adverse Drug Reactions
and Abnormal Changes in Laboratory Parameters in
Clinical Trials for Antimicrobial Agents (Japanese
Society of Chemotherapy).2)
(2) Abnormal changes in laboratory parameters
Abnormal changes in laboratory parameters will be as-
sessed by referring to Assessment Criteria for Adverse
Drug Reactions and Abnormal Changes in Laboratory
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Parameters in Clinical Trials for Antimicrobial Agents
(Japanese Society of Chemotherapy).2)
8.4.2 Secondary efﬁcacy and safety variables
There has been an increase in bridging studies in recent years, and
some clinical trials have used the assessment criteria and methods that
are used in Western countries. As such, the timing of assessment may
vary. It is therefore necessary to investigate and carefully consider
these issues in accordance with the characteristics of the trial when
selecting variables. The primary and secondary variables should be







8.5 Administration dosage and method
Once informed consent has been obtained, the principal
investigator or subinvestigators will administer the in-
vestigational product orally/intravenously in accordance
with the dosage and administrations shown in the table
below.
Volume per dose Frequency (per day)
 mg X times
H17009 mg Y times
8.6 Administration period
The period should be set in accordance with the objective of the trial.
E.g. 7-day administration period
Administration will generally be seven days (168
hours) (possibly eight calendar days). However, ad-
ministration will be terminated early or discontinued
within this period if the objective of the therapy is achieved
or the patient meets the discontinuation criteria described
below. If a longer administration period is necessary, the
drug may be administered for up to 14 days (or 15 calendar
days).
8.7 Duration of the clinical trial
The duration of the clinical trial is between the day of
consent and the ﬁnal observation day.
The trial does not necessarily ﬁnish at the completion of the adminis-
tration of the investigational product.
8.8 Target population
XXX cases
8.9 Pretreatment and concomitant therapies
8.9.1 Pretreatment and meals
The rules regarding pretreatment and meals should be described. In
particular, rules should be drawn up in regard to antimicrobial agent(s)
that have been administered prior to the administration of the investi-
gational product.
8.9.2 Concomitant drugs and therapies
If particular concomitant therapies are conducted, the procedures and
prohibitions governing these therapies should be described.
The name of the concomitant drug that will be used during
the clinical trial, the dosage and administrations, duration
and indications treated during the clinical trial will be re-
corded on the case report form. In the case of a concomitant
therapy, the name, method, duration and indications
treated will be recorded on the case report form. Drugs or
therapies used in the treatment of an adverse event will be
recorded in the section, “Action taken for adverse event”
on the case report form.
8.9.3 Prohibited concomitant drugs and therapies
These drugs and therapies should be set up in accordance with the
characteristics of the investigational product or clinical trial. The drugs
for which careful attention is required when used in conjunction with
the investigational product should be described in a different section
(8.9.4).
The drugs and therapies listed below are prohibited for use
in conjunction with the investigational product. However,
when these drugs or therapies are deemed necessary for the
beneﬁt of the subject, administration of the investigational
product will be discontinued. Administration of the investi-
gational product will be discontinued for any subject found
to be receiving any of these drugs or therapies.
1) Other oral antimicrobial agents or antimicrobial
injections
2) Human immunoglobulin preparations
3) Colony-stimulating factor preparations (G-CSF etc.)
4) Adrenocorticosteroids (equivalent to 10mg or more of
prednisolone per day by means of inhalation or general
administration)
5) Continuous administration of antipyretic analgesics
(Occasional use is acceptable.)
6) Other drugs and medical instruments under
development
7) Bronchial washing
8) Other drugs that should be prohibited due to the characteristics of
the investigational product (e.g. Valproic acid when carbapenem is
the investigational product, and NSAID when new quinolone is the
investigational product.)
8.9.4 Concomitant drugs and therapies that need careful
attention
Interactions are known to occur between the drugs similar
to the investigational product and the drugs and therapies
that are listed below. If these drugs are being used, careful
attention and consideration must be given to their inﬂuence
on the efﬁcacy of the investigational product and the
beneﬁts to the subject.
The drugs and therapies should be speciﬁed in accordance with the
characteristics of the investigational product and clinical trial.
Example: Theophylline when new quinolone is the investigational
product; The clinical trial that is assessing the efﬁcacy of the investiga-
tional product when it is used in conjunction with a small dose of
macrolide; Local therapy around the tonsils or pharynx of patients with
acute respiratory tract infections (use of antimicrobials, disinfectants,
anti-inﬂammatory drugs, tonsillectomy, pharyngectomy and puncture);
A small dose of aspirin as an antithrombotic; Use of NSAID.
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8.10 Maintenance of blinding
In the case of the comparative test, the following sections (8.11 and
8.12) are also necessary.
Blinding will be carried out using the randomization proce-
dure. This will be conducted by the person responsible for
assigning the investigational product. The investigational
product will be indistinguishable from the control drug.
The treatment assignment list will be stored (by the per-
son responsible for assigning the investigational product)
until the time of unsealing. Blindness will be maintained for
all people relevant to this clinical trial, except for the person
responsible for assigning the investigational product.
The sponsor will prevent unblinding by reclaiming the
investigational product after the clinical trial has been com-
pleted and the treatment assignment list is unsealed. If the
investigational product is reclaimed prior to unsealing,
blindness will be maintained by the person responsible
for assigning the investigational product by checking the
quantities of the unused investigational product, place
them in the original box, seal the box, and return it to the
sponsor.
8.11 Unsealing procedure
The treatment assignment list will be unsealed after all case
report forms are completed and the data for analysis is
ﬁnalized.
9. Efﬁcacy and safety variables and ﬂow chart
9.1 Observation parameters, test parameters and
investigation parameters, and timing
The parameters and timing of observations and tests will vary in accor-
dance with the objectives of the clinical trial or the characteristics of the
investigational product.
9.1.1 Observation parameters, test parameters and investi-
gation parameters
1) Patient information
The following subject information will be described in
the case report form:
Subject ID code, initials, date of birth, sex, weight,
(height), type of patient (outpatient/inpatient), name
of diagnosed infectious disease and its severity, as well
as the name, stage and severity of the underlying
disease and complications, the seriousness of the
patient’s condition, disease history, allergy history,
and any antimicrobial agents that were administered
during the period beginning 7 days prior to the com-
mencement of administration and ending on the day
before the commencement of administration of the in-
vestigational product. The underlying disease and all
complications will be documented and circled if there is
any possibility that they will inﬂuence the indications
studied.
The severity of infectious diseases, the underlying
disease, and complications will be assessed on the basis
of the severity criteria for infectious diseases and the
severity criteria for the underlying disease and complica-
tions set down in Clinical Evaluation Methods for New
Antimicrobial Agents for the Treatment of Respiratory
Tract Infections (Japanese Society of Chemotherapy).1)
The following categories will be used for assessment and





2) Efﬁcacy evaluation parameters
(1) Subjective symptoms and objective ﬁndings
The following symptoms and ﬁndings will be investi-
gated on a day speciﬁed for consultation or interview.
The symptoms and ﬁndings investigated for acute
respiratory tract infections are body temperature,
cough, pharyngeal pain, tonsil pain, coating of pus, the
accumulation of pus, purulent secretion, redness and
swelling. The symptoms and ﬁndings investigated for
pneumonia and secondary infection of chronic respira-
tory illness are body temperature, cough, sputum
(volume and type), chest pain, breathing difﬁculty,
rhonchus, dehydration and cyanosis. Observed symp-
toms and ﬁndings will be recorded in the case report
form in accordance with the following criteria. If body
temperature is measured more than once in one day,
the highest temperature for that day will be recorded.
<Assessment criteria>
A. Acute respiratory tract infections
[1] Body temperature: Actual measurement (Body
temperature will be measured, even if there is no
fever.)
[2] Cough:  (disturbing sleep),  (moderate),
 (mild),  (none)
[3] Pharyngeal pain:  (severe)  (moderate), 
(mild),  (none)
[4] Tonsil pain:  (severe)  (moderate), 
(mild),  (none)
[5] Coating of pus and accumulation of pus: 
(severe)  (moderate),  (mild),  (none)
[6] Purulent secretion:  (severe)  (moderate),
 (mild),  (none)
[7] Redness:  (severe)  (moderate),  (mild),
 (none)
[8] Swelling:  (severe)  (moderate),  (mild),
 (none)
B. Pneumonia and secondary infection of chronic
respiratory illness
[1] Body temperature: Actual measurement (Body
temperature will be measured even if there is no
fever.)
[2] Cough:  (disturbing sleep),  (moderate),
 (mild),  (none)
[3] Sputum volume: The following ﬁve levels
 (100mL or more per day)
 (50mL or more and not more than 100mL
per day)
 (10 mL or more and not more than 50mL per
day)
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 (Not more than 10mL per day)
 (None)
[4] Sputum type: P (purulent), PM (purulent and
mucous), M (mucous)
[5] Breathing difﬁculty:  (Hugh-Jones: more than
((),  (H-J: (),  (none)
[6] Chest pain:  (yes),  (no)
[7] Rhonchus:  (signiﬁcant),  (mild),  (none)
[8] Dehydration:  (yes),  (no)
[9] Cyanosis:  (yes),  (no)
(2) Chest X-rays (pneumonia and secondary infection of
chronic respiratory illness)
It is beneﬁcial to perform CT scans of the chest, in
addition to chest X-rays.
Chest X-rays will deﬁnitely be taken prior to the
commencement of administration and seven days fol-
lowing the commencement of administration (or at the
time of completion/discontinuation). A sketch will be
drawn in the case report form. If the subject is suffering
from pneumonia, compulsory X-rays will also be taken
three days after the commencement of administration.
(3) Microbiological testing
In the case of acute respiratory tract infections, mi-
crobes will be isolated from the eiterbelag/plug of pus,
the purulent secretion, or a pharynx swab, then
identiﬁed and counted. In the case of pneumonia and
secondary infection of chronic respiratory illness, mi-
crobes will be isolated from sputum, and then identiﬁed
and counted. This will be done in order to identify the
pathogenic bacteria and microbe substitute. The results
will be recorded in the case report form. Even if the
microbes that are detected are the microbes that form
normal microﬂora, the name of each species of microbe
will be recorded on the form. Smear testing and Gram’s
staining of the sputum will be conducted in accordance
with the smear specimen preparation procedure. The
results and comments of the ﬁndings will be docu-
mented in the case report form.
<Test for drug sensitivity to pathogenic bacteria and
microbe substitute>
The pathogenic microbes and microbe substitute that
are separated at each medical institution will be sent to
the central laboratory facility in order to measure their
sensitivity to drugs. As a general rule, serial dilution for
measuring the MIC will be prepared in accordance with
NCCLS rules. If the MIC and microbiological efﬁcacy
clearly do not match, it will be beneﬁcial to change the
microbial volume for measuring the MIC and/or mea-
suring MBC.
3) Safety evaluation parameters
(1) Adverse events
i) Deﬁnition of an adverse event
Any unfavorable medical occurrence happening be-
tween the commencement of administration of the in-
vestigational product and the ﬁnal observation (in a
patient who has received the investigational product),
regardless of the existence of a causal relationship with
this investigational product. However, events that occur
due to the investigational product’s lack of efﬁcacy will
be assessed to determine whether they are adverse
events by considering the nature and degree of each
event. In general, adverse events include the following.
[1] Recently developed diseases or symptoms
[2] Deterioration of complications
[3] Accidents
[4] Deterioration of laboratory test values
[5] Unfavorable ﬁndings that appear after the com-
pletion of drug-taking
[6] Unfavorable ﬁndings due to drug interactions
[7] The effects of polypharmacy (determined by a
doctor)
[8] The effects of drug abuse
[9] The onset of dependency
ii) Observation of adverse events
[1] The onset or deterioration of the condition of sub-
jective symptoms and objective ﬁndings, the dete-
rioration of the condition of the underlying disease
and complications, and the onset of coincidental
symptoms
In order to collect information on an adverse event
that has occurred in a subject following administra-
tion of the investigational product, the principal
investigator or subinvestigators will conduct an in-
vestigation, (between the commencement of the
administration of the investigational product and
the ﬁnal observation day) by documenting the
subject’s voluntary report and the interview
ﬁndings. If any observed adverse events do not dis-
appear (or if the subject does not recover) during
the clinical trial period, a follow-up investigation
will be conducted following the completion of the
clinical trial, and the outcome will be documented
in the case report form.
[2] Abnormal changes in laboratory parameters
If clinically signiﬁcant abnormal values are ob-
served in laboratory tests between the commence-
ment of administration of the investigational
product and the time of completion or discontinua-
tion of administration, and these values do not nor-
malize (or do not return to the previous levels), a
follow-up investigation will be conducted following
the completion of the clinical trial. The results will
be documented in the case report form.
The adverse event follow-up period should be established in accor-
dance with the characteristics of the investigational product. In all
cases, the original observation period should continue until the ﬁnal
observation day; Laboratory tests (especially invasive tests) during the
follow-up period are not compulsory, except in the case that the labo-
ratory test at the end of the adverse event follow-up period is set as
compulsory in the clinical trial protocol, or when the principal investi-
gator or subinvestigators regard it as clinically necessary.
4) Laboratory tests
The laboratory parameters that are considered necessary to evaluate
safety should be established in accordance with the characteristics of
the investigational product.
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The serum antibody tests (Mycoplasma antibody titer,
Chlamydia antibody titer and Legionella antibody titer) do
not need to be conducted on any speciﬁc day because of the
time it takes for the values to become positive.
Special tests for determining the pathogenic bacteria should be clearly
documented in accordance with the clinical trial.
Recently, if Mycoplasma, Chlamydia or Legionella are the microbes
treated in a clinical trial, identiﬁcation by means of culturing or PCR,
may be required in addition to immunological testing.
5) Therapies following the completion or discontinuation
of administration of the investigational product
The principal investigator or subinvestigators will record
the therapies undertaken between the completion or dis-
continuation of administration of the investigational
product and the ﬁnal observation day. Whether the use
of antimicrobial agents during this period is necessary or
not will be considered very carefully because it will
inﬂuence the ﬁnal evaluation. If agents are used, the
objective of their use will be clearly documented on the
case report form.
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If antimicrobial agents are used before the ﬁnal evaluation, the ﬁnal
evaluation will be regarded as “Indications studied were not cured”.
Therefore, the use of antimicrobial agents following administration of
the investigational product as a means of preventing a recurrence of
the disease should be considered very carefully.
6) Follow-up for subjects who do not visit the hospital (trial
site)
If any subjects do not visit the hospital and it is difﬁcult
to continue treatment, the principal investigator or
subinvestigators will contact them by telephone, letter,
or other means of communication in order to encourage
them to visit the hospital. It may be necessary to conduct
the follow-up over the telephone. The date of investiga-
tion, drug taking status, reasons for not continuing to
visit, and whether or not there is or was an adverse event
will be documented in the case report form. It will be
recorded in the case report form that the follow-up can-
not be conducted (due to relocation or change of resi-
dence etc.), if such is the case.
7) Drug-taking instructions and drug-taking status
If the investigational product is an oral drug, this title should be as
above. If the investigational product is an injection, a title such as
“Status of administration” should be written at this section and instruc-
tions for recording the status in the case report form should be de-
scribed here.
Example for an oral drug
The principal investigator or subinvestigators will instruct
subjects to bring their drug-taking diary and the remaining
investigational product, every time they visit. The principal
investigator or subinvestigators will check the drug-taking
status of each subject and record it in the case report form.
9.1.2 Flow chart
Observations and tests will be conducted in accordance with
the above table. The results will be recorded on the case
report form.
9.2 Efﬁcacy and safety variables and evaluation methods
9.2.1 Efﬁcacy evaluation
1) Efﬁcacy evaluation three days after the commencement
of administration
(1) Clinical efﬁcacy (three days after the commencement of
administration)
The clinical efﬁcacy of the investigational product will
be assessed on the basis of the subjective symptoms,
objective ﬁndings and laboratory test values (and
shading in the chest X-rays in the case of pneumonia)
between or during the period prior to the commence-
ment of administration and three days after the com-
mencement of administration. The clinical efﬁcacy
evaluation criteria in Clinical Evaluation Methods for
New Antimicrobial Agents for the Treatment of Respi-
ratory Tract Infections (Japanese Society of Chemo-
therapy)1) will be used. The results of the assessment
(one of the following categories) will be documented in
the case report form.
1. Effective
2. Ineffective
3. Not possible to assess
2) Efﬁcacy evaluation at the end of treatment (EOT)
(1) Clinical efﬁcacy (EOT)
The clinical efﬁcacy of the investigational product will
be assessed on the basis of subjective symptoms,
objective ﬁndings and laboratory test values (and shad-
ing in the chest X-rays in the case of pneumonia) be-
tween or during the period prior to the commencement
of administration and the completion or discontinua-
tion of administration. The clinical efﬁcacy evaluation
criteria in Clinical Evaluation Methods for New An-
timicrobial Agents for the Treatment of Respiratory
Tract Infections (Japanese Society of Chemotherapy)1)
will be used. The results of the assessment (one of the





3. Not possible to assess
(2) Assessment of shading in chest X-rays
If the subject is suffering from pneumonia, chest X-ray
shading will be assessed on the basis of the criteria in
Clinical Evaluation Methods for New Antimicrobial
Agents for the Treatment of Respiratory Tract Infec-
tions (Japanese Society of Chemotherapy).1) The score
(between 011) will be recorded in the case report
form.
(3) Microbiological efﬁcacy for each species of pathogenic
bacteria
The name of microbes that are thought to be patho-
genic bacteria will be circled on the case report form.
Furthermore, the pathogenic bacteria will be deter-
mined by comprehensive consideration of the progress
of each subject’s clinical condition, as well as the micro-
biological test results. The information obtained from
the results of the quantitative culture and Gram’s stain-
ing will also be considered for evaluation. If Gram’s





4. Not possible to assess
Among the species of bacteria detected at the comple-
tion or discontinuation of administration, the name of
the species of bacteria that are suspected to have
emerged following administration will be marked on
the case report form.
<Bacteria that emerged following administration>
The species of bacteria that emerged following ad-
ministration were those whose numbers were below
the detection limit in the test prior to the commence-
ment of administration but were detected following
the com-mencement of administration. The qualitative
and quantitative measurements for these species at
the completion of administration (or at the ﬁnal ob-
servation) are 2  or more, and 104 cfu/ml or more,
respectively.
However, Neisseria, α-Streptococcus and other non-
pathogenic microbes in the respiratory tract will be
excluded unless there are legitimate reasons for their
inclusion. If a subject’s condition is assessed as superin-
fection, the newly detected bacteria will be treated as
having emerged following administration, even if the
qualitative and quantitative measurements for such
bacteria are less than the ﬁgures stated above.
(4) Microbiological efﬁcacy (EOT)
i) Pathogenic bacteria
Microbiological efﬁcacy will be assessed on the basis of
results of the tests conducted prior to administration,
three days after the commencement of administration,
and at the completion or discontinuation of administra-
tion. The microbiological efﬁcacy evaluation criteria in
Clinical Evaluation Methods for New Antimicrobial
Agents for the Treatment of Respiratory Tract Infec-
tions (Japanese Society of Chemotherapy)1) will be
used. One of the following categories will be recorded
in the case report form. In the assessment of efﬁcacy,
comprehensive evaluation, as described in section (3),
is required.




5. Not possible to assess
ii) Bacteria that emerged following administration
The emergence or otherwise of bacteria following ad-
ministration will be assessed at the time of the comple-
tion or discontinuation of administration and will be
documented in the case report form. Such bacteria will
be assessed in terms of the following categories, and
one of the categories will be recorded.
1. Overgrowth of microbe substitute (Infections and/or
symptoms due to the bacteria that emerged following
administration are not observed.)
2. Superinfection (Infections and/or symptoms due to
the bacteria that emerged following administration are
observed.)
3) Efﬁcacy evaluation at the ﬁnal observation (end of
study: EOS)
The evaluation methods and assessment criteria will be
described when the ﬁnal evaluation is drawn up.
Example
(1) Final evaluation
For cases in which administration of other antimi-
crobial agents was not necessary, the ﬁnal observation
will be conducted following the completion or discon-
tinuation of administration of the investigational prod-
uct, and assessment will be conducted on the basis of
the following criteria.
If administration of other antimicrobial agents is car-
ried out, the ﬁnal evaluation will be assessed as “Indica-
tions studied were not cured”.
<Cases in which EOS and EOT are at different times
from each other>
The ﬁnal evaluation will be based primarily on the as-
sessment of clinical efﬁcacy at the EOS (7 to 10 days
following the completion or discontinuation of adminis-
tration for cases of acute respiratory tract infections
and pneumonia, and 721 days for cases of secondary
infection due to chronic respiratory illness). One of the
following assessment categories for the clinical efﬁcacy
will be recorded on the case report form.
1. Cured (or effective)
2. Uncured (or ineffective)
3. Not possible to assess
<Cases in which EOS and EOT are at the same time>
The ﬁnal evaluation will be based on the clinical
and microbiological efﬁcacy at the EOS (7 to 10 days
following the completion or discontinuation of adminis-
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tration for cases of acute respiratory tract infections
and pneumonia, and 721 days for cases of secondary
infection due to chronic respiratory illness). One of the




3. Not possible to assess
The following is an example of assessment criteria for
the ﬁnal evaluation.
9.2.2 Safety evaluation
1) Abnormal laboratory test values
The laboratory test values will be assessed to determine
whether they are normal or abnormal. This assessment
will be documented in the case report form. Abnormal-
ity will be deﬁned as any deviation from the standard
range of values set by each trial site. If the test is carried
out at the central laboratory facility, standard range
values will be those set by the central laboratory. If the
trial site does not have standard range values for any of
the parameters, the principal investigator or subinves-
tigators will set the standard range values for these
parameters by referring to the “Guideline for Labora-
tory Test Methods” etc. and submit the values to the
sponsor. The results of these parameters will then be
assessed accordingly.
2) Adverse events
(1) Documentation of adverse events in the case report
form
[1] Onset or deterioration of subjective symptoms
and objective ﬁndings, deterioration of underlying dis-
ease or complications, and the onset of coincidental
symptoms
If an adverse event such as the onset or deterioration of
subjective symptoms and objective ﬁndings, deteriora-
tion of the underlying disease or complications, or the
onset of coincidental symptoms occurs between or dur-
ing the period before the commencement of adminis-
tration of the investigational product and the ﬁnal
observation day, the principal investigator or subin-
vestigators will document, in the case report form, the
type of adverse event, the day of onset, action taken,
the outcome, severity, seriousness, causal relationship
with the investigational product, and the basis of assess-
ment. This documentation will be carried out in accor-
dance with the assessment criteria set out in the
following section.
[2] Abnormal changes in laboratory parameters
The principal investigator or subinvestigators will docu-
ment the parameters whose values change from “nor-
mal” to “abnormal”, or which were “abnormal” and
deteriorated, between or during the period prior to the
commencement of administration of the investigational
product and the completion or discontinuation of ad-
ministration. This documentation will be carried out
with reference to the standard range of values speciﬁed
by the trial site and “Assessment criteria for adverse
drug reactions and abnormal changes in laboratory pa-
rameters in clinical trials of antimicrobial agents”.2) The
principal investigator or subinvestigators will assess
whether these changes are clinically signiﬁcant or not.
The reasons for those assessed as “not signiﬁcant” will
be documented in the case report form. The name of
the laboratory parameters assessed as “signiﬁcant”, as
well as the date on which they are veriﬁed, action taken,
outcome, severity, seriousness, causal relationship with
the investigational product, and the basis of each assess-
ment will be documented in the case report form in
accordance with the assessment criteria set out in the
following section.
(2) Assessment criteria for adverse events
[1] Type of adverse event
The type of each adverse event will be recorded in the
case report form. If the adverse event is an abnormal
change in laboratory parameters, the name of the pa-
rameter and the change (increase or decrease) will be
recorded in the case report form.
[2] Date of onset
The date of the onset, or the date that the event was
discovered, will be recorded in the case report form.
Final evaluation assessment criteria
Assessment at the ﬁnal Clinical efﬁcacy
observation Effective Ineffective Not possible to assess
Disappeared (no bacteria
emerged following Cured Uncured Not possible to assess
administration)
Decreased




Recrudescence Uncured Uncured Not possible to assess
Double infection
Super infection














[3] Action taken in response to the adverse event
i) Administration status of the investigational
product
The administration status of the investigational
product will be assessed and one of the following
categories will be recorded in the case report form.
1. Continuing/Completed
2. Amount decreased/Temporarily suspended
3. Discontinued
In the case of discontinuation, the person respon-
sible for the decision (the subject or physician) will
be speciﬁed in the case report form.
ii) Action taken
It will be recorded in the case report form whether
or not action was taken in response to each adverse
event. If action was taken, the details will also be
recorded.
[4] Outcomes of adverse events
The outcome of each adverse event will be assessed in
terms of one of the following categories, and the date
on which it is veriﬁed will be recorded in the case report
form.
i) The onset or deterioration of the condition of
subjective symptoms or objective ﬁndings, the dete-
rioration of underlying disease or complications, or
the onset of coincidental symptoms





6. Death/Not possible to follow-up
ii) Abnormal changes in laboratory parameters





6. Death/Not possible to follow-up
If the outcome is unknown, the reasons for this sit-
uation will be documented in the case report form.
[5] Severity of adverse events
The severity of each adverse event will be assessed by
referring to the “Assessment criteria for adverse drug
reactions and abnormal changes in laboratory param-
eters in clinical trials for antimicrobial agents”2), and





[6] Seriousness of adverse events
All adverse events will be assessed to determine
whether they are serious or not by referring to the
deﬁnition of “serious adverse event”. If assessed as
serious, it will be recorded on the case report form.
1. Serious
2. Not serious
[7] Causal relationship with the investigational
product
Each causal relationship with the investigational prod-
uct will be assessed in terms of one of the following
categories. The basis of assessment will also be docu-
mented in the comments column.
1. Deﬁnitely related
An adverse event will be regarded as deﬁnitely re-
lated if a clear correlation is observed with respect
to timing (the period following the discontinuation
of administration will be included), and evidence
that indicates a clear relationship is observed, such
as that described below.
• Similar symptoms/signs were observed when
the investigational product was accidentally re-
administered.
• Drug sensitivity tests (lymphocyte culture test,
skin test etc.) are positive.
2. Probably related
An adverse event will be regarded as probably re-
lated if a clear correlation is observed with respect
to timing (the period following the discontinuation
of administration will be included) and factors such
as the primary disease, complications, concomitant
drugs and concomitant therapies will be excluded as
possible causes.
3. Possibly related
An adverse event will be regarded as possibly re-
lated if a clear correlation is observed with respect
to timing (the period following the discontinuation
of administration will be included) and factors such
as the primary disease, complications, concomitant
drugs and concomitant therapies are suspected as
the cause, but the investigational product cannot be
excluded as the cause.
4. Not related
An adverse event will be regarded as not related if
a clear correlation is not observed with respect to
timing (the period following the discontinuation of
the administration will be included).
If an adverse event is assessed as 1, 2 or 3, it is
regarded as “related to the investigational product”
and is categorized as “abnormal changes in labora-
tory parameters due to the investigational product”
or an “adverse drug reaction”.
10. Safety assurance for all subjects
10.1 Fundamental
Appropriate selection criteria will be set so that subjects for
whom safety is not guaranteed cannot be enrolled in the
trial. The results of the screening tests will be used to deter-
mine whether subjects will be enrolled or not.
During the clinical trial, it will be ensured that investiga-
tors are always aware of the condition of the health of each
subject by means of daily observation in the case of inpa-
tients, and observation at every visit in the case of outpa-
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tients. A method of contact will be prearranged in case of
emergency. Collection and communication of safety infor-
mation considered to be related to the investigational prod-
uct will be carried out continuously. When an adverse event
occurs, the safety of subjects will be assured through the
provision of the appropriate medical treatment, such as
decreasing the dosage or discontinuing administration of
the investigational product. An adverse event investigation
method (which would be conducted by the efﬁcacy and
safety evaluation committee), treatment for the serious ad-
verse event, and the procedure for decoding during the
clinical trial will be established. These rules will ensure that
there will be communication with the trial site(s), that deci-
sions regarding continuation/discontinuation of the clinical
trial will be taken appropriately, and that the safety of sub-
jects will be assured.
10.1.1 Efﬁcacy and safety evaluation committee (Indepen-
dent data-monitoring committee)
This committee consists of physicians who are not involved in the
clinical trial. It is independent from the coordinating committee.
This committee will be established if assessment by an inde-
pendent organization consisting of physicians who are not
involved in the clinical trial is necessary because additional
attention must be paid to safety and clinical efﬁcacy within
the trial, or because the primary efﬁcacy and safety vari-
ables of the trial are subjective. If the committee is estab-
lished, the objectives and roles of the committee should be
described.
Example
XXXX, the indication studied, sometimes involves a serious
outcome. Therefore, the sponsor will collect the case
report form of each subject who received the investigational
product. If a problem arises, it will be reported to this
committee. Safety and clinical efﬁcacy will be examined by
this committee, and the feasibility of continuation of the
clinical trial will be assessed. This committee will provide
the results of their examination and assessment to the
sponsor.
10.2 Serious adverse events
10.2.1 Deﬁnition of a serious adverse event
(1) Death (Leading to death)
(2) Event that may lead to death (Life-threatening)
(3) Event that requires the subject to be hospitalized or the
duration of hospitalization to be extended to allow for
treatment
(4) Disability (permanent or signiﬁcant disability or
dysfunction)
(5) Event that may lead to disability (Medically important
condition)
(6) Serious event that ranks below any of the events de-
scribed in (1) to (5) (Medically important condition)
(7) Congenital disease or abnormality in progeny (Event
that brings congenital anomaly)
(8) Any event that the principal investigator or
subinvestigators judge as serious
(9) Any event that the sponsor judges as serious
10.2.2 Action taken at onset
The principal investigator or subinvestigators will carry out
appropriate emergency treatment for the following serious
adverse events, and ask specialists to diagnose the event in
order to determine the cause. If a relationship between an
adverse event and the investigational product cannot be
ruled out, the principal investigator or subinvestigators will
promptly (i.e. within 24 hours of discovery) report the ad-
verse event to the head of each trial site and the sponsor
(monitor), either in person, by telephone or fax. (This will
apply to all adverse events except those categorized “not
related”.) The principal investigator or subinvestigators will
then submit the “Serious adverse event during clinical trial
(brief report)” form within three days, as well as the “Seri-
ous adverse event during clinical trial (detailed report)”
within ten days to the head of the trial site and the sponsor.
Furthermore, the head of the trial site will provide the
principal investigator with instructions, based on the recom-
mendations of the institutional review board, in regard to
the continuation of the clinical trial. The principal investiga-
tor or subinvestigators will report on the adverse events that
were judged to have no causal relationship with the investi-
gational product (events categorized as “not related”) in the
same manner as described above. The adverse events will
be reported within 24 hours of discovery. The brief report
will be submitted to the head of the trial site and the spon-
sor within three days, and the full report will be submitted
within ten days.
10.3 Decoding procedure during the clinical trial
This section should be included in the comparative test.
If an adverse event occurs and the principal investigator or
subinvestigators judge that unblinding is necessary to pro-
tect the safety of subjects, the decision will be reported to
the sponsor. The sponsor will ﬁrst conﬁrm that the contents
of the case report form of the subject who had the adverse
event is ﬁnalized, and then ask the person responsible for
assigning the investigational product, to break the emer-
gency key codes.
10.4 Expected adverse drug reactions
10.4.1 Expected adverse drug reactions (including abnor-
mal changes in laboratory parameters)
The adverse drug reactions and abnormal changes in labo-
ratory parameters that are expected, on the basis of results
from non-clinical studies and previous clinical trials, are
shown below. The adverse drug reactions and abnormal
changes in laboratory parameters to which attention needs
to be paid, are also shown below. The principal investigator,
subinvestigators, and the trial staff will all be well aware of
these reactions in order to ensure the safety of subjects.
1) Important points from the results of the non-clinical
studies
Important points from the results of the basic studies (non-clinical
studies) should be described here.
Example
It is known from XXX test that it has mutagenicity. There-
fore, long-term use of high doses should be avoided.
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Reactions that occurred in previous clinical trials should be described
here.
2) Adverse drug reactions and abnormal changes in labora-
tory parameters that were observed in previous clinical
trials
By the phase  clinical trial,  was observed in %
of subjects (/) and  was observed in % of
subjects (/). Abnormal changes were observed in
(parameter). Therefore, attention should be paid to such
reactions and changes when examining subjects.
3) Serious adverse drug reactions related to similar types
of drugs (known information regarding adverse drug
reactions)
Example
• Central nervous system-related symptoms such as
convulsions and impaired consciousness
• Shock or anaphylactic symptoms
• Mucocutaneous ocular syndrome (Stevens-Johnson
syndrome), toxic epidermal necrosis (Lyell syndrome)
• Hepatitis, icterus
• Bronchospasm, interstitial pneumonia, pulmonary
inﬁltration with eosinophilia syndrome (PIE syndrome)
• Pancytopenia, myelosuppression, agranulocytosis,
hemolytic anemia
• Serious renal diseases such as acute renal failure
• Serious colitis such as pseudomembranous colitis ac-
companying hemafecia
• Thrombophlebitis
4) Other important points
Refer to the investigator’s brochure in regard to other
adverse drug reactions that have occurred with similar
drugs.
10.4.2 Action taken at onset
1) The onset or deterioration of subjective symptoms and
objective ﬁndings, deterioration of underlying disease
and complications, and the onset of coincidental
symptoms
The principal investigator or subinvestigators will
conduct appropriate treatment and take all possible
measures to ensure the subject’s safety until the reaction
attenuates or the principal investigator or subinvestiga-
tors judge that no further treatment is necessary. The
reactions will be documented in detail in the “Adverse
event” section. Even if action cannot be taken because
the subject has changed residence or hospital, follow-up
by means of telephone or letters will be conducted to
determine the outcome. The ﬁndings of the follow-up
will be documented in the case report form.
2) Abnormal changes in laboratory parameters
In the case that the principal investigator or
subinvestigators judge that the abnormal changes in
laboratory parameters are clinically signiﬁcant, the prin-
cipal investigator or subinvestigators will continue to
observe the values until they return to within the stan-
dard range or improve, or the principal investigator or
subinvestigators judge that no further observation is
necessary. The ﬁndings from observation will be docu-
mented in the case report form.
11. Discontinuation criteria and procedure
11.1 Discontinuation criteria
The principal investigator or subinvestigators will cease ad-
ministration of the investigational product to the subject if
any of the following criteria apply.
(1) Subject or next-of-kin request
(2) No improvement is observed in the condition of symp-
toms and ﬁndings and it is judged that continuation is
not appropriate.
(3) Continuation is difﬁcult due to the onset of an adverse
event.
(4) The condition of the underlying disease/complications
has deteriorated and it is judged that continuation is not
appropriate.
(5) It is found, after the commencement of the clinical trial,
that a subject’s disease is not included in the indications
studied.
(6) It is found that the subject does not satisfy the inclusion/
exclusion* criteria after the commencement of the clini-
cal trial.
(7) It is judged that administration of prohibited concomi-
tant drugs is necessary.
(8) The subject does not visit the trial site.
(9) Other criteria for which the principal investigator
or subinvestigators accept the necessity of the
discontinuation.
*If the subject was not excluded on the basis of the
exclusion criteria at the commencement of administra-
tion, but he/she comes into conﬂict with the criteria due
to a change in condition during the period of adminis-
tration, the principal investigator or subinvestigators
will judge whether continuation of administration of
the investigational product is inappropriate (difﬁcult)
or not. If continuation is judged as appropriate (pos-
sible), the reason for the judgement will be documented
in the case report form.
11.2 Discontinuation procedure
If the principal investigator or subinvestigators become
aware of any subject who should not continue on the
basis of the discontinuation criteria (11.1), or any of the
following three situations occurs, administration of the in-
vestigational product will be discontinued for that subject
and the situation will be explained to the subject. EOS
observations and tests will be conducted at the time of
discontinuation. Following discontinuation, subjects will
receive alternative therapy or appropriate treatment. Out-
patients will be notiﬁed by telephone and instructed to
cease taking the investigational product and to visit the trial
site promptly for an alternative therapy or appropriate
treatment.
(1) The sponsor instructs the principal investigator(s) or
subinvestigators to prematurely terminate or suspend
the entire clinical trial (refer to 14.2).
(2) The sponsor instructs the principal investigator or
subinvestigators to prematurely terminate or suspend
the clinical trial at a speciﬁc trial site (refer to 14.3).
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(3) A principal investigator decides to prematurely termi-
nate or suspend the clinical trial due to concerns about
the safety of the investigational product.
12. Statistical analysis
12.1 Quality control and assurance of data
12.1.1 Quality control of data
The monitoring committee and data management commit-
tee will control the quality of data in accordance with “stan-
dard operating procedures”.
The sponsor will implement and maintain quality control
systems to ensure the reliability of the data that are relevant
to the clinical study at each stage of data handling. Finaliza-
tion of case information (collection of case report forms,
data checks, input, changes and amendments) and manage-
ment of the data prior to the time of analysis will be carried
out in accordance with standard operating procedures.
12.1.2 Quality assurance of data




12.3 Determination of sample size
It is important to determine the sample size before commencing the
trial. In comparative tests, consideration should be given to ensuring
that the balance is not biased against the control drug.
The case selection criteria for efﬁcacy and safety (adverse
drug reactions and abnormal changes in laboratory param-
eters) evaluation will be as follows. Cases that are selected
for analysis are regarded as the “per protocol set” (PPS).
Cases that do not meet GCP will be excluded from the
samples for all efﬁcacy evaluations. Cases to which the in-
vestigational product will not be administered will be
excluded from all evaluations.
12.3.1 Efﬁcacy
Cases will be adopted for the sample group to evaluate
efﬁcacy if the investigational product was taken/adminis-
tered for three days or more, and if the principal investiga-
tor or subinvestigators assessed ﬁnal clinical efﬁcacy.
However, cases that violate any of the following criteria will
be excluded.
[1] Cases that deviate from the inclusion criteria or meet
the exclusion criteria.
[2] Cases that do not satisfy the selection criteria for
evaluation set down in Clinical Evaluation Methods
for New Antimicrobial Agents for the Treatment
of Respiratory Tract Infections (Japanese Society of
Chemotherapy).1
[3] Correct dosage and administrations are not
maintained.*
[4] Prohibited concomitant drugs/therapy are involved.
[5] Cases that violate the discontinuation criteria
[6] Cases in which observations were not recorded at the
commencement, at the time of discontinuation, or at
the completion of administration.
*As a general rule, cases in which 80120% of the
expected total volume of the investigational product
(from the commencement until the completion or dis-
continuation) has been taken/administered can be
included. However, cases in which drug-taking/admin-
istration has been missed on two consecutive occasions
will be excluded.
If the investigational product is a drug requiring one administration
daily, appropriate criteria should be set.
12.3.2 Safety (Adverse drug reactions)
Cases in which the investigational product has been taken/
administered at least once will be included.
12.3.3 Safety (Abnormal changes in laboratory
parameters)
Cases for which the speciﬁed parameters have been tested
prior to the commencement and at the time of discontinua-
tion or completion of administration will be included. How-
ever, cases in which the tests were conducted during and at
the time of discontinuation or completion of administration
will be included in each safety evaluation parameter in ac-
cordance with the following table. Cases in which abnormal
changes in laboratory parameters have been observed will
always be included.
12.4 Statistical analysis plan
1) Purpose of analysis
Assessment variables that should be explored/conﬁrmed in the clinical
trial should be described here.
2) Primary efﬁcacy and safety variables
(1) Efﬁcacy
Example
Clinical efﬁcacy (efﬁcacy rate) at EOT
Inclusion criteria for each parameter
Time tested Pre-administration













Types of adverse drug reactions and abnormal changes in
laboratory parameters (incidence rate/number of occur-
rences) and their severity
They should be set in accordance with the characteristics of the clinical
trial.
3) Secondary efﬁcacy and safety variables
(1) Efﬁcacy
Example
Clinical efﬁcacy (efﬁcacy rate) three days after the com-
mencement of administration, microbiological efﬁcacy (dis-
appearance rate) at EOT, and microbiological efﬁcacy for
each pathogenic bacteria (disappearance rate)
(2) Safety
Example
The occurrence of any type of adverse event/adverse
drug reaction that can generally be described as 
(according to the glossary of adverse drug reactions)
(and the incidence of the reactions).
4) Primary background factors
Sex, age, weight, (height), diagnosis of the infection and
its severity, the existence of a underlying disease/com-
plications (and severity, if any), the existence of a un-
derlying disease/complications that may inﬂuence the
infection, and the seriousness of the subject’s condition.
It is important to clarify the method of analysis. It is
particularly important to clarify the test method and
conﬁdential interval for primary variables if the trial is
comparative or conﬁrmatory.
5) Method of analysis
(1) Analysis of the primary efﬁcacy and safety variables
In regard to clinical efﬁcacy, the efﬁcacy rate will be the
number of cases in which the clinical efﬁcacy is assessed
as “effective” in proportion to the total number of valid
cases selected for efﬁcacy analysis.
In regard to microbiological efﬁcacy, the efﬁcacy
rate will be the number of cases in which microbiologi-
cal efﬁcacy is assessed as “disappeared” in proportion
to the total number of valid cases selected for efﬁcacy
analysis, with the exclusion of cases in which microbio-
logical efﬁcacy was “Not possible to assess”.
In regard to safety, all adverse events whose causal
relationship with the investigational product cannot be
denied will be regarded as adverse drug reactions/
abnormal changes in laboratory parameters. The inci-
dence of adverse drug reactions will be the number
of cases in which adverse drug reactions occurred in
proportion to the total number of valid cases that
were selected for safety analysis of adverse drug
reactions.
The incidence of abnormal changes in laboratory
parameters will be the number of cases in which abnor-
mal changes in laboratory parameters occurred in pro-
portion to the total number of valid cases that were
selected for safety analysis of abnormal changes in
laboratory parameters. The actual number of cases for
each reaction/parameter will not be shown.
The incidence of each type of adverse drug reaction
will be the number of cases of each type in proportion
to the total number of valid cases selected for safety
analysis of adverse drug reactions. The incidence of
abnormal changes in each laboratory parameter will be
the number of cases in which abnormal changes in each
laboratory parameter occurred in proportion to the
total number of valid cases that satisfy the selection
criteria for safety analysis (as described in 12.3.3).
(2) Analysis of the secondary efﬁcacy and safety variables
The following demographic characteristics and charac-
teristics of other standard values will be summarized or
analyzed.
Sex, age, weight, (height), names of diagnosed infec-
tious diseases, the severity of the infectious diseases,
the existence of an underlying disease/complications
(and severity, if any), the existence of a primary disease/
complications that may inﬂuence the infection, the seri-
ousness of the subject’s condition, body temperature,
cough, sputum volume, sputum type, WBC count and
CRP. In the case of pneumonia, chest X-ray shading
will be included.
If pathogenic bacteria were analyzed, the name of
the species (or genus) will be used for categorization.
The microbiological efﬁcacy for each bacteria (disap-
pearance rate) will be the number of cultures that were
assessed as “disappeared” in proportion to the total
number of valid cultures for efﬁcacy analysis, with the
exclusion of cultures that were categorized as “Not pos-
sible to assess”.
In regard to the clinical efﬁcacy three days after the
commencement of administration, the efﬁcacy rate will
be the number of cases in which clinical efﬁcacy was
assessed as “effective” in proportion to the total num-
ber of valid cases selected for efﬁcacy analysis.
In regard to changes in symptoms/signs, analysis will
be carried out using all the cases that are valid for
efﬁcacy analysis.
The cure rate at the ﬁnal evaluation assessment will
be the number of cases that were categorized as
“cured” in proportion to the total number of valid cases
for efﬁcacy analysis.
6) Others
It should be remembered that exploratory analysis (analysis that was
later added to the planned analyses) is not primary analysis.
If necessary, exploratory analysis will be carried out in
order to determine the efﬁcacy and safety characteristics
of the investigational product.
7) Interim analysis
If interim analysis is conducted, the objective and meth-
ods will be described. The timing of analysis will be set in
accordance with the objective of the clinical trial.
13. Compliance, deviation, change and amendment of the
clinical trial protocol
13.1 Compliance with the protocol
This clinical trial will be conducted in accordance with the
protocol, as agreed to by the principal investigator(s) and
the sponsor.
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13.2 Deviation from the protocol or changes to the
protocol
If any change to the protocol has the potential to signiﬁ-
cantly inﬂuence the clinical trial or increase the risk to
which subjects are exposed, the principal investigator must
submit the proposed protocol amendment to the institu-
tional review board of the trial site. The proposed protocol
amendment must be reviewed and approved before enroll-
ing any new subjects.
A principal investigator cannot amend the protocol with-
out prior agreement of the sponsor, and without prior re-
view and documented approval from the institutional
review board, except where necessary to eliminate an im-
mediate hazard(s) to the trial subjects, or when the
change(s) involve only administrative aspects of the trial.
If a principal investigator changes the protocol to elimi-
nate an immediate hazard(s) to the trial subjects, documen-
tation of the implemented change will be submitted to the
head of each trial site, the institutional review board, and
the sponsor.
13.3 Amendment of the protocol
Amendment of the protocol will be decided through discus-
sion between the principal investigator(s) and the sponsor.
The institutional review board will arrange the discussion if
necessary. If it is decided to amend the protocol, the spon-
sor will notify the principal investigator and head of each
trial site. Notiﬁcation will be in writing and will include the
amendments and the reasons for the change.
14. Completion, premature termination or suspension of
the clinical trial
14.1 Completion of the clinical trial
The following situation will be regarded as the completion of the
clinical trial.
1) The completion of administration of the investigational
product (end of treatment: EOT)
If a ﬁnal observation is to be included in the protocol, it
should be noted that the completion of administration of
the investigational product (end of treatment: EOT) is
not the completion of the clinical trial (end of study:
EOS).
(1) The drug-taking/administration of the investigational
product is complete. (The investigational product was
taken/administered for seven days {or eight calendar
days} or the speciﬁed administered volume was taken/
administered, and the efﬁcacy assessment was con-
ducted at the completion of administration.) [Example
of the 7-day administration period]
(2) It was judged that the objective of the treatment was
achieved.
2) Completion of the clinical trial
The ﬁnal observation was conducted and the speciﬁed
tests and evaluations were carried out (end of study:
EOS).
The principal investigator will submit the EOS report
(including the GCP compliance status) to the head of the
trial site as soon as the clinical trial is complete. The head
of the trial site will notify the institutional review board
and the sponsor, and provide them with a summary  re-
port.
14.2 Premature termination or suspension of the entire
clinical trial
The sponsor will prematurely terminate or suspend the en-
tire clinical trial if continuation of the clinical trial becomes
impossible due to the onset of serious adverse events, etc. If
such a situation arises, the sponsor will promptly notify the
head of each trial site and inform them of the premature
termination or suspension of the entire clinical trial and the
reason for it. Notiﬁcation will be in writing. The head of
each trial site will notify the principal investigator and insti-
tutional review board, in writing.
14.3 Premature termination or suspension of the clinical
trial at a speciﬁc trial site
The sponsor will prematurely terminate or suspend the
clinical trial at a speciﬁc trial site if any of the following
situations occur. If any such situations arise, the sponsor will
promptly notify the head of the trial site and inform them of
the premature termination or suspension of the entire
clinical trial and the reason for it. Notiﬁcation will be in
writing.
The head of the trial site will notify the principal investi-
gator and the institutional review board, in writing. Upon
receiving the notice, the principal investigator will follow
the procedure speciﬁed at the trial site.
1) The continuation of the clinical trial becomes impossible
due to the onset of serious adverse events.
2) The trial site breaches ordinance No. 24 (related to
GCP), the protocol, or the clinical trial contract, and as a
result, a correct clinical trial cannot be carried out. In
such cases, the contract with the trial site will be can-
celled and the clinical trial at the trial site will be prema-
turely terminated (except when it is necessary to
eliminate an immediate hazard(s) to trial subjects, or in
other medically important cases).
15. Case report form
15.1 Composition and submission of the case report form
The principal investigator or subinvestigators will ﬁll in the
case report form for each subject from whom consent was
obtained as soon as the ﬁnal observation is conducted or
participation is discontinued. If a subinvestigator ﬁlls in the
case report form, the subinvestigator will print his/her name
and sign or stamp the form and submit it to the principal
investigator for veriﬁcation of the contents. The principal
investigator will print his/her name and sign or stamp the
form once it has been conﬁrmed as valid. The signature or
stamp that are used on the case report form will be the same
as that on the “list of signatures and stamps” that will be
submitted to the sponsor before preparing the case report
form.
15.2 Changes or amendments to the case report form
Changes or amendments to the case report form will be
conducted in accordance with the following procedure.
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(1) The principal investigator or subinvestigators will pre-
pare, change or amend the case report form in accor-
dance with the “Instruction guideline for preparing,
changing or amending the case report form”, which will
be produced separately and in advance.
(2) To change or amend a record, rule double lines through
the original parts, making sure that the original parts
are still readable. Write the date, and sign or stamp the
alteration. The signature and stamp of the principal
investigator or subinvestigators must be that which ap-
pears in the section “Name of the principal investigator
or subinvestigators”. If the amendment is major or sig-
niﬁcant (i.e. the date of consent, causal relationship,
evaluation assessment and drug-taking status), the
reason and date of the amendment will be written and
signed or stamped.
(3) In the case that a member of the trial staff changes or
amends the case report form, rule double lines through
the original parts, as described above, and write the
date of the change/amendment. The principal investiga-
tor or subinvestigators must sign or stamp the changed/
amended part.
(4) If changes or amendments to the case report form
become necessary, the principal investigator will make
a record of the changes or amendments to the case
report form and submit the record to the sponsor.
(5) If a part of the case report form is changed or amended
after the principal investigator has conﬁrmed its con-
tents (i.e. the date of the changes/amendments is later
than the date of composition), the principal investigator
will check the changed/amended part and write the date
of conﬁrmation, print his/her name and sign or stamp
the alteration each time it is necessary.
(6) The principal investigator will store a copy of the case
report form and other records including records of the
changes or amendments to the case report form.
15.3 Cautions for ﬁlling in the case report form
Trial staff may ﬁll in the case report form (e.g. copying
demographics, observations and test results from the origi-
nal source), except for any information that is related to
medical evaluation and assessment.
(1) The “JSC-0X clinical trial case report form” will be
used.
(2) The principal investigator or subinvestigators will pre-
pare, change or amend the case report form in accor-
dance with the “Instruction guideline for preparing,
changing or amending the case report form”, which is
produced separately and in advance.
(3) Pen or ballpoint pen will be used so that writing cannot
be erased.
(4) The case report form will be prepared for all subjects
from whom consent is obtained. However, for subjects
who did not receive the investigational product, only
the sections for demographics, observations and test
results will be ﬁlled in.
(5) Insert a dash (or similar) for items not tested or exam-
ined in order to distinguish these parts from parts that
have been overlooked.
(6) Conﬁrm that the data in the case report form are consis-
tent with the source data. If there is any contradiction,
the principal investigator will prepare a report on this
matter stating the reason and submit the report to the
sponsor.
(7) The principal investigator or subinvestigators will con-
ﬁrm all contents; sign or stamp the changed/amended
part; print his/her name and sign or stamp in the section
“Name of the principal investigator or subinvestiga-
tors”; and write the date of composition/conﬁrmation.
16. Direct access to the source data/documents
16.1 Specifying the source documents
The source documents should be speciﬁed in advance in accordance
with the characteristics of the clinical trial.
The following items are not always recorded on the
patient’s card (or similar) within the trial site. Therefore,
the information written in the case report form or the test
results attached to the case report form will be regarded as
the source documents for these items.
Example
• Conﬁrmation of the fulﬁllment of inclusion/exclusion
criteria
• Severity of infectious disease, stage and severity of under-
lying disease/complications, the reason for discontinua-
tion of antimicrobial agents prior to the administration of
the investigational product
• Drug-taking/administration status, sketch of chest X-ray
shading and score
• Indications treated by concomitant drugs or therapies
• Assessment of each species of pathogenic bacteria and
bacteria that emerge following administration
• Comments on the smear test
• Results of the microbiological test conducted by the cen-
tral laboratory
• Assessment of laboratory parameters (normal or abnor-
mal) and signiﬁcant changes
• Severity and seriousness of adverse events, the date that
the outcome was determined, the reason why the out-
come is unknown, the existence of a causal relationship
and reason for the decision
• Drug concentration measurement result
• Reason for discontinuation of administration of the in-
vestigational product
• Objective and efﬁcacy of antimicrobial agents used fol-
lowing the completion or discontinuation of administra-
tion of the investigational product
• Methods of follow-up, date of follow-up, reasons for not
continuing to visit
• Clinical efﬁcacy assessment and basis for it
• Microbiological efﬁcacy
• Final evaluation
16.2 The monitor was appointed by the sponsor
The monitor will directly access the source documents
in order to conﬁrm that there are no contradictions be-
tween the patient cards at the trial site and the case report
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forms. The monitor will apply for direct access to the source
documents in accordance with the method speciﬁed by each
trial site, and access them on a designated date and in a
predetermined manner. The principal investigator or
subinvestigators will review the work of the monitor, and
change or amend, if necessary, the contents of the case
report form, in accordance with the procedure for changes/
amendments.
17. Quality control and assurance for the clinical trial
17.1 Quality control
Quality control and assurance will be achieved by comply-
ing with GCP; as well as by standardizing the methods of
preparing the case report form, the handling and manage-
ment of the case report form and source data, the monitor-
ing, direct access to the source data, evaluation and
assessment; and by investigating the appropriateness of
such methods.
17.1.1 Compliance with GCP
This clinical trial will be conducted in accordance with the
protocol, and in compliance with the Declaration of
Helsinki and Clause 3, Article 14 and Clause 2, Article 80 of
the Pharmaceutical Affairs Law and GCP.
The principal investigator(s), in association with the
sponsor, agree to the contents of the protocol and case
report form, and pledge, prior to conducting the clinical
trial, that they will comply with the protocol and case report
form in all respects.
17.1.2 Management and handling of the case report form
data
The sponsor will implement and maintain quality control
systems to ensure the reliability of the data that are relevant
to the clinical study at each stage of data handling. Finaliza-
tion of case information (collection of case report forms,
data checks, input, changes and amendments) and manage-
ment of data prior to the time of analysis will be carried out
in accordance with standard operating procedures.
17.1.3 Monitoring
The monitor will be appointed by the sponsor. The monitor
will provide necessary information on conducting the clini-
cal trial to the principal investigator(s), subinvestigators,
trial staff and drug management ofﬁcer(s), as well as explain
and discuss the procedure of the clinical trial (protocol) and
the method of managing the investigational product.
The monitor will visit the trial sites periodically (or when
the need arises) during the clinical trial period and conduct
the following activities.
(1) Verify the appropriateness of the trial site, investiga-
tors, the laboratory and other aspects of the clinical
trial.
(2) Verify the investigational product.
(3) Verify the appropriateness of instructions and deci-
sions of the head of the trial site, and verify compli-
ance with GCP.
(4) Verify that consent was obtained from the subjects.
(5) Provide information to the head of each trial site and
the principal investigator(s), and conﬁrm that they
have received the information.
(6) Verify that the investigator is enrolling only eligible
subjects.
(7) Check the progress of the clinical trial.
(8) Verify that source documents and other trial records
are accurate, complete and stored.
(9) Verify that the investigator has provided all the re-
quired reports and notiﬁcations, and that these docu-
ments are accurate.
(10) Inform the principal investigator of any case report
form entry errors, omissions, or invalidity. This will be
achieved by comparing the case report form with the
source data or other relevant documents. The monitor
should ensure that appropriate corrections, additions
or deletions are made.
(11) Verify that all adverse events are adequately reported.
(12) Check data storage at the trial site.
(13) Communicate with investigators in regard to any
deviations from the protocol and GCP, and take
appropriate action to prevent any recurrence of the
deviations.
17.1.4 Direct access to the source documents
The principal investigator and clinical trial site will make
available all source documents or other relevant do-
cuments at the trial site in order to assist the investigations
of the monitor, auditor, the institutional review board or
regulatory authority. These investigations are carried out
in order to verify that the clinical trial is being carried
out appropriately, and that the reliability of the data is
maintained.
17.1.5 Standardization and validity of evaluation and
assessment
1) Efﬁcacy is assessed on the basis of the clinical efﬁcacy
assessment criteria set down in Clinical Evaluation
Methods for New Antimicrobial Agents for the Treat-
ment of Respiratory Tract Infections (Japanese Society
of Chemotherapy).1)
2) Microbiological tests will be carried out at the central
laboratory and trial sites. The tests will be conducted
in accordance with the standard operating procedures
established at each institution.
3) Abnormal changes in laboratory parameters will be as-
sessed by referring Assessment criteria for adverse drug
reactions and abnormal changes in laboratory param-
eters in clinical trials of antimicrobial agents (Japanese
Society of Chemotherapy).2) For the parameters whose
criteria are not documented, the principal investigator or
subinvestigators will form their own assessment on the
basis of standard medical practice.
4) The validity of the evaluation and assessment (diagnosis,
severity of disease, clinical efﬁcacy, microbiological
efﬁcacy, chest X-ray shading and safety) by the principal
investigator or subinvestigators will be veriﬁed by the
clinical trial coordinating committee for each case. The
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issues raised by the committee will be discussed with the
principal investigator or subinvestigators. The principal
investigator will consider the discussion and make a ﬁnal
decision on each issue.
17.2 Quality assurance
The following activities will be conducted by the sponsor’s
auditing department.
18. Ethical conduct of the clinical trial
18.1 Institutional review board
18.1.1 Review
The validity of this clinical trial will be investigated by the
institutional review board that is nominated by the head of
the trial site. If the institutional review board orders a
change in the protocol, the principal investigator and
subinvestigators of each trial site, the clinical trial coordi-
nating committee and the sponsor will discuss the issue and
formulate a response.
The sponsor will submit the updated versions of the fol-
lowing documents to the head of the trial site if the institu-
tional review board requests such.
1) Protocol (whose contents will have been agreed to by
the principal investigator(s))
2) Case report form
3) Consent form and written information (prepared by
the principal investigator)
4) The investigator’s brochure
5) Documents related to the anticipated costings of the
clinical trial
6) Documents related to the payment (if any) of subjects
and compensation for trial-related injury
7) Resumes of the principal investigator(s) and
subinvestigators
8) Up-to-date documents related to the status of the
clinical trial (If the trial has continued for one year or
more, documents should be submitted at least once a
year, or when the institutional review board requests
them.)
9) Documents related to the safety of subjects (serious
adverse event report, new important information)
10) Other documents that the institutional review board
considers necessary
18.1.2 Continuous review by the institutional review board
The institutional review board will continuously review the
clinical trial if necessary. Moreover, if the trial has con-
tinued for one year or more, the institutional review board
will request up-to-date documents that describe the status
of the trial at least once a year in order to ensure the clinical
trial is being conducted safely.
18.2 Protection of human rights
18.2.1 Ethical conduct of the clinical trial
This clinical trial will be conducted in accordance with the
protocol, and in compliance with the Declaration of
Helsinki and Clause 3, Article 14 and Clause 2, Article 80 of
the Pharmaceutical Affairs Law and GCP.
18.2.3 The conﬁdentiality of subjects
Careful attention will be paid to the protection of the hu-
man rights of the subjects. The identity of each subject will
remain conﬁdential by using initials and a subject ID code.
The monitor, auditor, institutional review board and regula-
tory authority will maintain the conﬁdentiality of each sub-
ject when they access source data.
19. Storing records
19.1 The sponsor
The GCP record management ofﬁcer will be appointed by
the sponsor. The GCP record management ofﬁcer will store
all documents and records required to this trial (the request
for the clinical trial, records, the minutes of the institutional
review board, reports on the results of discussions, con-
tracts, the clinical trial protocol, case report form, the com-
prehensive clinical trial report, the database, and records
and test results related to analyses). The documents and
records will be stored for the period speciﬁed in Clause 2–3,
Article 26 of the Regulations of the Pharmaceutical Affairs
Law. All documents and records required to this trial are
speciﬁed in the GCP.
When the investigational product has been approved for
manufacture, or a decision has been made to discontinue its
development, the sponsor will notify the clinical trial site in
writing.
19.2 The principal investigator
The head of the clinical trial site will place the principal
investigator in charge of storing records. He/she will be
responsible for storing records in accordance with the regu-
lations at the trial site and section 19.3.
19.3 Clinical trial site
The person who is appointed by the head of the clinical trial
site to be responsible for storing records, will store docu-
ments and records that are required by GCP to be stored at
the trial site (source documents, contracts, consent forms,
written information and instructions on handling the inves-
tigational product). He/she will store these documents for
three years from either the date of approval for manufac-
ture as a pharmaceutical product, the date of the early
termination of the clinical trial, or the date of the comple-
tion of the clinical trial, whichever occurs last. The docu-
ments will be stored in a location speciﬁed by the trial site.
When the speciﬁed period for storage has elapsed, the per-
son responsible for storing records will obtain approval
from the sponsor before destroying any documents. If the
place of storage changes due to moving etc., a record of the
new location will be maintained. The head of the trial site
and the person responsible for storing the records will en-
sure that records are not lost or destroyed, and will make
available any records required during the moving process.
When the storage period has elapsed, the sponsor will
notify the trial site.
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20. Payment and insurance
20.1 Payment
In a multicenter trial, each trial site may have their own regulations in
regard paying the subjects (e.g. payment may be payment in kind).
Therefore, this section (20.1 Payment) may be written separately to the
main protocol.
XXXX yen per visit will be paid to outpatients as a coopera-
tion fee/transportation expenses. XXXX yen will be paid to
inpatients at the times of hospitalization and discharge dur-
ing the trial period. In regard to the method of payment,
each trial site will comply with their own regulations.
20.2 Compensation for trial-related injury and insurance
The sponsor will take out the following insurance in order
to compensate subjects for trial-related injury.
• Type of insurance and the name of the insurance
company
[1] Type of insurance (e.g. General liability insurance that
includes clinical trials)
[2] Name of insurance company
If the subject receives a trial-related injury, the medical
institution will treat the subject and take any other nec-
essary action. The sponsor will be liable for compensa-
tion for trial-related injury, as may arise. The subject
will not bear any expenses in obtaining proof, such as
proof of a causal relationship between the injury and
this clinical trial. If the medical institution is obliged to
compensate the subject, the sponsor will reimburse the
medical institution for all expenses, except in the fol-
lowing cases.
1) A signiﬁcant deviation from GCP or the protocol by the
principal investigator or subinvestigators (except for
medically unavoidable circumstances such as to elimi-
nate immediate hazards to the subjects)
2) Intentional or non-intentional malpractice and/or negli-
gence by the principal investigator or subinvestigators
3) Self-induced injury or negligence on the part of the
subject
If compensation or reparation is necessary due to trial-
related injury, the medical institution will notify the
sponsor promptly.
21. Agreement on publication
When any person involved in this clinical trial intends to
present the results or information in the public arena, such
as at conferences or in journals, he/she will discuss the con-
tents of any such publication with the sponsor in order to
obtain approval. The conﬁdentiality of subjects will be
maintained in the publication.
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23. The basis for components
The scientiﬁc basis for each component should be described here by
referring to materials such as guidelines.
1) Clinical trial design
The trial will be designed along the lines of a clearly
deﬁned objective and the speciﬁc characteristics of the
investigational product. The basis for the design will be
described in accordance with Guidelines for Clinical
Efﬁcacy of Antimicrobial Agents.4)
2) Inclusion criteria
The basis for the inclusion criteria will be described by
referring to Guidelines for Clinical Efﬁcacy of Antimi-
crobial Agents4) and Clinical Evaluation Methods
for New Antimicrobial Agents for the Treatment of
Respiratory Tract Infections (Japanese Society of
Chemotherapy).1)
3) Exclusion criteria
The basis for the exclusion criteria will be described by
referring to Guidelines for Clinical Efﬁcacy of Anti-
microbial Agents4), General Guidelines for Clinical
Evaluation of Antimicrobial Agents5), and Clinical
Evaluation Methods for New Antimicrobial Agents
for the Treatment of Respiratory Tract Infections
(Japanese Society of Chemotherapy).1)
4) Dosage and administrations
The basis for dosage and administrations will be
described by referring to Breakpoint for Septicemia
and Respiratory Tract Infections (Japanese Society of
Chemotherapy)6), and by considering the results of
non-clinical trials and previous clinical trials.
5) Administration period
The basis for the period of administration will be de-
scribed in accordance with Clinical Evaluation Meth-
ods for New Antimicrobial Agents for the Treatment
of Respiratory Tract Infections (Japanese Society of
Chemotherapy).1)
6) Completion and discontinuation criteria
The basis for the completion and discontinuation crite-
319
ria will be described in accordance with the characteris-
tics of the clinical trial.
7) Pretreatment and meals
The basis for pretreatment and conditions regarding
meals will be described in accordance with the charac-
teristics of the clinical trial.
8) Prohibited concomitant drugs/therapies
The basis for the prohibition of concomitant drugs/
therapies will be described in accordance with the
characteristics of the clinical trial.
9) Concomitant drugs/therapies that need careful
attention
The basis of the need for careful attention for certain
concomitant drugs/therapies will be described in accor-
dance with the characteristics of the clinical trial.
10) Observation and test parameters
The basis for observation and test parameters will be
described by referring to Clinical Evaluation Methods
for New Antimicrobial Agents for the Treatment of
Respiratory Tract Infections (Japanese Society of Che-
motherapy).1)
11) Time of observation and tests
The basis for the times that are set for observation and
tests will be described by referring to Clinical Evalua-
tion Methods for New Antimicrobial Agents for the
Treatment of Respiratory Tract Infections (Japanese
Society of Chemotherapy).1)
12) Treatment following the completion or discontinuation
of administration of the investigational product
[Example] This was established in order to collect in-
formation on the efﬁcacy of the investigational product
from the treatments that were conducted following the
completion or discontinuation of administration of the
investigational product.
13) Follow-up for subjects who did not continue visiting
[Example] This was established in order to ensure the
safety of subjects who did not continue visiting.
14) Assessment related to demographics
The basis for severity criteria for infectious diseases,
primary diseases and complications, which are related
to the inclusion/exclusion criteria, will be described
by referring to Clinical Evaluation Methods for
New Antimicrobial Agents for the Treatment of
Respiratory Tract Infections (Japanese Society of
Chemotherapy).1)
15) Primary efﬁcacy and safety variables
The basis for variables that are thought to be necessary
in order to achieve the objective of the clinical trial will
be described.
16) Secondary efﬁcacy and safety variables
The basis for variables that are thought to be necessary
to explore/conﬁrm the characteristics of the investiga-
tional product and achieve the objective of the clinical
trial will be described.
17) Entries that ensure the safety of subjects
The basis for the entries that ensure the safety of sub-
jects will be described by referring the results of safety
issues in non-clinical trials and previous clinical trials.
18) Case population
The basis for the setting the number of cases in order to
achieve the objective of the clinical trial should be de-
scribed using statistical and clinical reasons. The basis
for the predicted value (expected efﬁcacy rate etc.) will
be described.
